Printer Friendly

Signaling mechanisms and disrupted cytoskeleton in the diphenyl ditelluride neurotoxicity.

1. Introduction

Tellurium (Te) is an element sharing the same group of sulfur and selenium in the periodic table; that is, it is the heaviest of the stable chalcogens (group 16) and is classified as a metalloid. In contrast to oxygen, sulfur, and selenium, tellurium has no essential physiological role in cell biology [1]. However, due to its chemical versatility, Te has been extensively used in chemistry, particularly, in organic synthesis (for comprehensive reviews about the importance of tellurium in organic synthesis, see [2-6]). In addition to its use in organic synthesis, tellurium is widely used in the vulcanization of rubber and in metal-oxidizing solutions to tarnish metals, such as silver. More recently, tellurium (as CdTe, HgTe, and PbTe) has also been used in the composition of quantum dots (QD) in thermoelectric materials, in digital versatile disk-random access memory (DVD-RAM), and in DVD-recordable disks (DVD-RW) [79]. The presence of tellurium in different types of electronic materials and nanomaterials is an important health issue. These materials usually contain a variety of toxic elements and there is a paucity of research about the environmental and occupational toxicity of those materials [10-13]. Most importantly, the fate of electronic material constituents is unknown, but tellurium can be released in the environment either as elemental tellurium or as more reactive cation forms. The toxicity of elemental tellurium and its ionic forms have also been little explored in the literature [14,15]. After its release in the environment, tellurium can be biomethylated to more volatile intermediates and, consequently, can be mobilized from soil or from aquatic bodies to the atmosphere [10,16]. In short, the presence of tellurium in the environment is expected to increase in the next years or decades.

Here in this review, we will give emphasis to diphenyl ditelluride, the simplest of the diaryl ditellurides, which is used as an intermediate in organic synthesis [17]. This organic compound of tellurium, diphenyl ditelluride or [(PhTe).sub.2], has been described to possess very contrasting and interesting biological activities [18-23], including antioxidant properties stronger than its selenium analog, the diphenyl diselenide or [(PhSe).sub.2] [23]. However, the toxicological properties of this compound seem to be more striking than its potential pharmacological properties (for review, see [17]). Despite this, we must emphasize that the question of tellurium toxicity may be related to the stability of the carbon-tellurium bond (C-Te bond) [24-29]. For instance, we have observed that diethyl 2-phenyl-2 tellurophenyl vinylphosphonate (DPTVP) was nontoxic to mice when tested at doses much higher than that of [(PhTe).sub.2] [26], which indicated that perhaps some organic chemical forms of tellurium can be safe for therapeutic use. Indeed, there are some indications in the literature that tellurium could be of potential pharmacological importance (see, for instance, [30-39]). Unfortunately, the rational study of tellurium toxicity is incipient and there is no systematic study of organoselenium and organotellurium toxicity. The approach to this important question has been limited to few laboratories and most of the studies are empirical in nature [17, 29, 37, 38, 40-46]. Thus, the progress in the field of organochalcogen compounds as potential pharmacological agents will require new more refined approaches other than simple empirical testing of new compounds (see, for instance, [45]). In order to offer elements to support rational protocols to study the toxicity and pharmacology of organochalcogens, particularly tellurides, we have been investigating the in vitro and in vivo neurotoxicity of the simplest and the prototypal of the diaryl ditelluride molecules, that is, [(PhTe).sub.2] in rats, using the intermediate filaments as the targets of organotellurium toxicity (Figure 1).

Most importantly, evidence from our group in the last years has shown that, beyond the gross neurotoxic actions described in the CNS of rodents [17], in vivo exposure to [(PhTe).sub.2] and ex vivo quantification of telluride effects on neural cells of rats indicated serious disruption of the homeostasis of cytoskeletal proteins in a spatiotemporal manner. Neurofilaments (NFs), microtubule-associated proteins (MAPs), and Tau make up the dynamic cytoskeletal architecture of neurons. Phosphorylation/dephosphorylation of these cytoskeletal proteins is a dynamic process regulated by many kinases/phosphatases which, in turn, are downstream of multiple signaling cascades. Aberrantly phosphorylated cytoskeletal proteins are associated with disrupted cytoskeleton, characteristic of neuronal damage in several human neurodegenerative diseases. Consequently, in this review, we will focus on recent insights into the neurotoxic actions of [(PhTe).sub.2] on the cytoskeleton. Particularly, we will consider experimental evidence of the signal transduction pathways involved in the misregulation of the phosphorylating system associated with intermediate filament (IF) proteins in neural cells. We will focus on studies performed in vivo and in semi-intact brain preparations, such as acute brain slices in view of the preservation of an integrated communication network.

2. An Overview of Tellurium Toxicity

The toxicity of tellurium has been little explored in the literature. Indeed, the exposure of humans to tellurium has been rare [1, 14, 17] and this perhaps explains the paucity in the studies of tellurium toxicity. However, as indicated above, the use of tellurium in organic synthesis, the debate that organic forms of tellurium could have pharmacological and therapeutic properties [30-34], and its use in electronic materials indicate that more studies about the molecular mechanisms of its toxicity are needed, particularly, in view of its potential neurotoxicity in mammals [1,17,43,47-49].

The identification of tellurium molecular and cellular targets is highly desirable from toxicological, physiological, and biochemical point of view. In the case of mammals, the target organ or system seems to vary depending on the type and the developmental stage of tellurium exposure. Reports of acute human intoxication are rare and there are only 2 cases of heavy intoxication of adults (see below) and in those cases, the administration of a solution containing the inorganic Te(IV) targeted multiple tissues [50]. However, at that time, no molecular endpoint of toxicity was assessed [50]. Tellurium in its elemental form can be either reduced to Te-2 or oxidized to [Te.sup.+4] or [Te.sup.+6] [51]. The anionic reduced form of tellurium is very unstable and the cationic forms are much more stable than that of Te-2. Indeed, Te(IV) and Te(VI) can interact with thiol groups and this interaction is involved in the toxicity of inorganic tellurite and tellurate (Figure 2). Tellurium in organic molecules can also undergo redox chemistry after interacting and oxidizing thiol groups. Thus, in view of its big size, tellurium behaves more as redox active metal than a nonmetal. This explains the ability of its cationic forms to oxidize thiolates and possibly selenolates [52-57]. In a similar way to selenite (Se(IV)), tellurite can inhibit thiol containing enzymes and this can be the molecular basis of tellurium toxicity (Figure 2). In the case of elemental tellurium, inhibition of squalene monooxidase, which has thiol groups in its active site, is an important step in tellurium neurotoxicity [17]. Since elemental tellurium is expected to have "weak chemical reactivity," its toxic effects after interacting with living cells must require its oxidation to cationic forms (Te(IV) and Te(VI)). Recently, we have demonstrated that some important selenoenzymes (for instance, glutathione peroxidase and thioredoxin reductase) can be targeted after exposure to diphenyl ditelluride [57] (Figure 3). Indeed, some organic forms of tellurium have been indicated as potential anticancer agents via inhibition of the selenoenzyme thioredoxin reductase [58-61]. The literature has also indicated that tellurium can replace selenium in some selenium proteins or amino acids [62, 63]. However, the extent or the existence of such substitution after in vivo exposure to tellurium has not been explored in detail.

3. Neurotoxicity of Inorganic Tellurium in Rodents

Elemental tellurium ingestion is toxic to rats and short-term exposure to high levels of [Te.sup.0] has been associated with transitory segmental demyelination of different types of fibers [65] and the inhibition of cholesterol synthesis, at the level of squalene epoxidase, in Schwann cells is an important metabolic process in Te-induced demyelination [49,66]. One key and primary ultrastructural observation in tellurium induced neuropathy is the presence of cytoplasmic lipid droplets in myelinating Schwann cells [48]. The chemical form of tellurium involved in squalene monooxygenase inhibition is unknown but tellurite (Te(IV), dimethyltellurium dichloride, and dimethyltelluride can inhibit the brain enzyme from rats [47, 67]. The mechanism of squalene monooxygenase enzyme inhibition by methyltelluride and tellurite is related to the oxidation of vicinal thiols in the enzyme (Figure 2). Other studies have also indicated the oxidation of endogenous thiol groups by organotellurium compounds [68, 69]. In effect, in a similar way to inorganic tellurium compounds, thiol-containing proteins seem to be preferential targets of organotellurium intoxication [17, 54-56, 69-74] (Figure 2(b)).

Developing brain is particularly sensitive to exogenous chemical agents [75-77]. Accordingly, the gestational exposure of rats to tellurium is associated with hydrocephalus [78-81], but not in rabbits [81]. However, the relation of hydrocephalus with cholesterol synthesis inhibition is not well defined. It is interesting to note that exposure of adult mice to [(PhTe).sub.2] was associated with the appearance of spherical, spongeous-like holes in the brain [17, 82]. In contrast to inorganic tellurium exposure [83], they were not characterized by the presence of lipofuscin [82].

One prototypal and interesting tellurium compound that has been studied in the literature is the inorganic tellurium molecule called AS-101 [34-39, 84]. This compound has interesting immunomodulatory properties and it was even proposed to be used in the treatment of AIDS [82] via inhibition of reverse transcriptase and immunomodulating properties [34]. The topical application of AS-101 has been demonstrated to stimulate the growth of hair and its use in the treatment of baldness was suggested in the past [39]. Despite these interesting observations, the therapeutic use of AS-101 is still a promise. The reasons for this are certainly related to the toxicity of this compound. In effect, the intoxication with AS-101 caused a myriad of signs of intoxication in rats, including reduction in food consumption and body weight, the presence of hind limb paresis, hematological changes, and histopathological alteration in several organs [85]. It is interesting to point out that we have observed that exposure of mice to high doses of [(PhTe).sub.2] was associated with hind limb paresis (unpublished observations). Furthermore, the typical garlic odor was reported after exposure to the inorganic AS-101 [85] and organic [(PhTe).sub.2]. In short, the toxicity of tellurium in either the inorganic or organic form has been little explored. At the molecular level, the redox transition from elemental or anionic tellurium to Te(IV), followed by interactions with endogenous thiol groups of low molecular weight molecules or with critical proteins, can explain the toxicity of tellurium. However, we have limited knowledge about the preferential protein targets of tellurium. Indeed, proteins having vicinal groups such as squalene monoepoxide and ALA-D [17, 84] can be important targets of tellurium intoxication. But the identification of primary target(s) of tellurium is still elusive. Here, we will show that [(PhTe).sub.2] disrupts the signaling pathways associated with phosphorylation and dephosphorylation of cytoskeletal elements in the central nervous system of rats, which can also be related to modulation of the redox state of some critical proteins by the tellurium atoms found in [(PhTe).sub.2].

4. Cases of Human Exposure to Tellurium

In two adults exposed accidentally to high quantities of sodium tellurite, the most characteristic observations were the presence of a garlic odor in the breath and cyanose, which were associated with methaemoglobin in the blood. These patients were exposed to about 2 g of sodium tellurite after retrograde pyelography examination, where sodium iodide was inadvertently replaced by sodium telluride. The presence of alkyltelluride (methyltelluride) was reported in one of the two patients that were lethally intoxicated with tellurite. Furthermore, the blood and/or the organs of the patients also exhaled a garlic odor. The color of organs was modified by the intoxication, reflecting possibly the deposition of elemental tellurium. Histological examination of different tissues demonstrated fatty degeneration and edema, which was more marked in liver than in brain, lungs, kidneys, spleen, and heart [86]. A third patient, who survived the minor intoxication with the same solution that killed the two other patients, received only small amount of sodium tellurite, because, on injecting the supposed "sodium iodide" solution, the catheter was blocked and withdrawn. He developed the typical garlic odor, but no additional symptoms of tellurium intoxication.

It is interesting to point out that acute or subacute exposure of mice to high doses of [(PhTe).sub.2] caused changes in the color of different organs and also the presence of garlic odor exhales from the body and organs of heavily intoxicated mice (unpublished observations). The garlic odor indicates that [(PhTe).sub.2] can release Te atom, which is metabolized to methylated forms of Te.

Less severe and nonfatal exposure to tellurium was reported in 2 children who ingested metal-oxidizing solutions containing tellurium. These solutions are normally used to clean silver objects [87] and were accidentally ingested by the children. Clinical signals of intoxication included vomiting, black discoloration of the oral mucosa, and garlic odor to the breath, which in one of the young children persisted for several months after the intoxication. The presence of garlic odor, though not a definitive clinical signal of tellurium exposure, should be considered as an important clinical feature by the health agents and may assist clinicians in the diagnosis of rare tellurium poisoning [87]. Two postgraduates investigating the potential therapeutic or industrial use of tellurium esters were exposed to tellurium hexafluoride gas in the laboratory [88]. The symptoms of intoxication included tellurium metallic taste in the mouth and presence of the typical garlic odor garlic in the breath, sweat, and urine. One of them became anorexic. Furthermore, they exhibited bluish-black patches in the webs of the fingers and, to a lesser degree, in the skin [88].

From a clinical point of view, it is important to emphasize that exposure of humans to levels of tellurium that did not produce overt signs of toxicity, for instance, after occupational exposure, was associated with garlic odor [89]. Furthermore, urinary levels of tellurium higher than 1 [micro]mol/mol creatine were associated with a higher likelihood of garlic odour reporting [89]. Thus, garlic odor, though not a conclusive cue, can help the physician in identifying intoxication or nonclinical exposure to tellurium.

5. An Overview on the Neurotoxicity of Diphenyl Ditelluride

Diphenyl ditelluride is the simplest of the aromatic, diorganoyl ditelluride compounds. It has been used in organic synthesis for a long time and in the last 15 years its toxicity and, particularly, neurotoxicity have been extensively studied. Indeed, developmental exposure to [(PhTe).sub.2] is teratogenic [17,19,90] and has been associated with long-term behavioral and neurochemical changes in rats [20-22, 91]. However, the majority of those studies have investigated the phenomena involved in the toxicity of [(PhTe).sub.2], but the molecular mechanism(s) involved in [(PhTe.sub.)]2 effects has (have) not been studied in detail. The general toxicity of [(PhTe).sub.2] seems to be related to oxidation of thiol-containing proteins as depicted in Figure 2(a) (for a comprehensive review, see [17, 69]). In this review, we will present the recent findings from our laboratory indicating that signaling mechanisms involved in regulating intermediate filament phosphorylation/dephosphorylation are important targets of [(PhTe).sub.2]. Our results also indicate that [(PhTe).sub.2] intoxication can be used to mimic some molecular changes found in important brain pathologies. Consequently, [(PhTe).sub.2] can be used as a tool to study pharmacological agents that could counteract the toxic effect of ditelluride on brain phosphorylating/ dephosphorylating system, for instance, organoselenium compounds with neuroprotective effects [17, 92, 93].

6. Physiology and Pathophysiology of the Cytoskeleton

The cytoskeleton, consisting of microtubules, intermediate filaments (IFs), and actin filaments, is indispensable for any eukaryotic cell. Cytoskeleton networks form complex intracellular structures that vary during the cell cycle and between different cell types according to their physiological role. IF proteins constitute the third main cytoskeletal system of vertebrate cells, expressed in a tissue- and development-specific manner.

According to the degree of sequence identity, IF proteins have been grouped into six sequence homology classes (SHC): acidic keratins (SHC I); basic keratins (SHC II); desmin; vimentin; and other mesenchymal IF proteins such as glial fibrillary acidic protein (GFAP) (SHC III); neurofilament (NF) proteins (ShC IV); lamins (SHC V); and an orphan group harboring the lens specific IF proteins phakinin and filensin [94, 95]. All of the IF proteins are considered to provide structural and mechanical support to the cell and are also involved in multiple cellular functions, including transport, protein and organelle targeting, migration, signaling, apoptosis, and protection from stress [96].

Neurofilaments are the neuron specific IFs. They consist of three subunits divided according to their molecular mass: NF heavy chain (NF-H: 190 kDa), NF middle chain (NF-M: 115 kDa), and NF light chain (NF-L: 68 kDa). In common with other members of the IF family, NF-H, NF-M, and NF-L each comprise a central alpha helical coil-coiled rod domain flanked by a variant amino-terminal globular head domain and a hypervariable carboxyl-terminal tail domain which differ in length among the subunits [97-99]. The tail domains of NF-M and NF-H are longer than the other IF proteins and extensively phosphorylated, forming lateral projections along the NF axis, responsible for NF spacing [100-102]. Thus, one of the functions of NFs in neurons is to control the axonal caliber and consequently nerve conductivity since the speed of conductivity of a nerve impulse is directly proportional to the caliber of the axon [103]. Also, myelination determines conduction velocity in larger axons and this is too associated with an increase in side-arm phosphorylation in NF-M and NF-H [104-108].

Neurofilaments are transported from the cell body where they are synthesized, to be delivered along the axon by a mechanism called axonal transport [109, 110]. The motors implicated in the anterograde transport are known to be kinesins, while the retrograde transport is mediated in association with dyneins, the same motor proteins involved in the fast axonal transport along microtubules 111]. It is known that carboxyl-terminal phosphorylation of NF-H progressively restricts association of NFs with kinesin and stimulates its interaction with dynein [112]. This event could represent one of the mechanisms by which aberrant carboxyl-terminal phosphorylation would slow NF axonal transport.

Astrocytes are important cytoarchitectural elements of the CNS; however, during the past few years, molecular and functional characterization of astroglial cells indicate that they have a much broader function than only supporting the neurons in the brain, as they have specialized functions in inducing and regulating the blood brain barrier (BBB), glutamate uptake, synaptic transmission, plasticity [113], and metabolic homeostasis of the brain [114,115]. Glial fibrillary acidic protein (GFAP) is the main IF protein expressed in mature astrocytes, where it is thought to help maintaining mechanical strength as well as the shape of cells. However, recent evidence has shown that GFAP plays a role in a variety of additional astrocyte functions, such as cell motility/migration, cell proliferation, glutamate homeostasis, neurite outgrowth, and injury/protection [113].

Because of their multiple roles in the cells, cytoskeletal protein components are among the main targets modified in response to extracellular signals that ultimately determine cell morphology and physiological role [116]. Consequently, it is not surprising that IFs are likely to be targeted in several genetically determined protein misfolding/aggregation diseases [117-119] as well as by a variety of pathogens [120] and toxins [92, 93].

Abnormally accumulated NFs are a pathological hallmark of many human neurodegenerative disorders, including amyotrophic lateral sclerosis [121], Alzheimer's disease [122, 123], Parkinson's disease [124, 125], Charcot-Marie-Tooth [126], giant axonal neuropathy [127], neuronal intermediate filament inclusion disease [128,129], and diabetic neuropathy [130,131]. Multiple factors can potentially induce the accumulation of NF, including dysregulation of NF gene expression, NF mutations, defective axonal transport, abnormal posttranslational modifications, and proteolysis [132]. Beyond their association with neural damage in inherited or agedependent neurodegenerative diseases, the disruption of NF homeostasis has been reported in response to toxic agents, such as beta, betaThminodipropionitrile (IDPN) [133-135], aluminium chloride [136], and methylmercury [92].

Astrocytes are also involved in a wide range of CNS pathologies, including trauma, ischaemia, and neurodegeneration. In such situations, the cells change both their morphology and expression of many genes leading to activation of astroglia, or astrogliosis [113, 137, 138]. Astrogliosis is characterized by the increase of IFs with accompanying cellular hypertrophy and an abnormal apparent increase in the number of astrocytes. Upregulation of IF proteins, in particular GFAP, but also vimentin and nestin, two IF proteins that are abundantly expressed in immature astrocytes, is regarded as the hallmark of astrogliosis [137,139]. However, the most remarkable evidence of the relevance of GFAP in the physiological roles of astrocytes in maintaining normal brain function is Alexander disease, the devastating leukodystrophy resulting from dominantly acting mutations in the coding region of GFAP [140]. These mutations have been associated with the presence of Rosenthal fibers, referring to intracellular protein aggregates containing GFAP and stress proteins in astrocytes [141].

7. Roles of Phosphorylation in

the Intermediate Filament Homeostasis

IF proteins are known to be phosphorylated on their head and tail domains and the dynamics of their phosphorylation/dephosphorylation plays a major role in regulating the structural organization and function of IFs in a cell-and tissue-specific manner [142-146]. Amino-terminal phosphorylation plays a major role in regulating the assembly/disassembly equilibrium of type III IFs as well as of NF-L and NF-M subunits of NFs [147]. In vivo and ex vivo studies from our group and others demonstrated that the phosphate groups on the amino-terminal head domain on GFAP, vimentin, and NF-L are added by second messengerdependent protein kinases, such as cAMP-dependent protein kinase (PKA), [Ca.sup.2+]/calmodulin-dependent protein kinase II (PKCaMII), and protein kinase C(PKC) [147-152]. Phosphorylation of Ser-8, Thr-7, Ser-13, and Ser-38 in the N-terminal region (head domain) of GFAP [153-155] causes disassembly of the IFs and, conversely, the action of protein phosphatases leading to dephosphorylation restores its ability to polymerize [155]. Moreover, in the C-terminal region (tail domain), phosphorylation of Ser-389 affects the interactions between GFAP and other IF proteins [156]. GFAP phosphorylation is possibly a key factor in astrocytes, since cells use phosphorylation/dephosphorylation levels to regulate the dynamic of the polymerization/depolymerization of these proteins promoting cell survival and physiological roles.

The assembly of NFs into a heteropolymer is dependent on the head domains of NF-L and NF-M and more specifically on the phosphorylation level of these domains. The major sites of in vivo phosphorylation on NF-L and NF-M subunits were identified to be Ser-55 (PKA) [149] and Ser-23 (PKA, PKC) [157, 158]. In vitro results point to Ser-57 (PKCaMII) [149,159], Ser-12, Ser-27, Ser-33, and Ser-51 (PKC) [160] as the main amino-terminal phosphorylation sites on NF subunits.

NFs are synthesized in the cell body, but they are extensively phosphorylated after they are transported into the axon [109, 110]. Phosphorylation sites in the tail domain of NF-M and NF-H are found in a glutamic acid rich region with Ser residues. These Ser residues can be phosphorylated by casein kinases I and II on the basis of their consensus sequences [161, 162]. However, NF-M and NF-H are extensively phosphorylated in phosphorylation sites located in LysSer-Pro (KSP) repeat regions of the tail domain of these subunits. Phosphorylation of the KSP repeats rends NF-H the most extensively phosphorylated molecule in the nervous system [163]. The KSP repeats are phosphorylated by proline-directed kinases such as Cdk5 [164], the mitogen-activated protein kinases (MAPK) such as Erk1/2, JNK, and p38MAPK [165-168], and glycogen synthase kinase 3 (GSK3) [167-169].

The phosphorylation of NFs occurs in close proximity to myelin sheaths [168]. Thus, myelination may be the signal needed to induce phosphorylation of NFs in axons and it is also possible that a signal from Schwann cells or oligodendrocytes might be related with Cdk5 and MAPK activation. The carboxyl-terminal tail regions of NF-M and NF-H protrude laterally from the filament backbone to form "side-arms" when phosphorylated. Phosphorylation of these sites regulates the interactions of NFs with each other and with other cytoskeletal structures, mediating the formation of a cytoskeletal lattice that supports the mature axon [143,145].

Moreover, carboxyl-terminal phosphorylation of NF-M and NF-H subunits has long been considered to regulate their axonal transport rate and in doing so to provide stability to mature axons [147]. The NFs are transported in the slow axonal transport component [170, 171], which results from binding to the fast motor proteins kinesin and dynein intermitted with prolonged pauses [172-174].

Evidence accumulated from studies of our group in the last years point to a critical role of the endogenous phosphorylation of IF proteins in response to a variety of signals in both physiological and pathological conditions [116,148,149, 152, 175-177], highlighting the cytoskeleton as a preferential target of the signal transduction pathways. Importantly, a large body of experimental evidence shows a link between misregulation of cell signaling mechanisms, disruption of IF phosphorylation, and cell damage in response to different stress signals. While the exact signaling pathways regulating NF phosphorylation remain elusive, there is increasing evidence that known signal transduction cascades are involved. These actions can be initiated by the activation of N-methyl-D-aspartate- (NMDA-), voltage-dependent [Ca.sup.2+] channels type L (L-VDCC), or G protein-coupled receptors, and the signal is transduced downstream of [Ca.sup.2+] mobilization or monomeric GTPase activation through different kinase/phosphatase pathways, regulating the dynamics of the cytoskeleton [148,149,152,176,177].

8. Assessing the Molecular Basis of Diphenyl Ditelluride Toxicity on the Cytoskeleton of Neural Cells

The brain is one of the major targets of [(PhTe).sub.2] toxic actions [17] (see above in Section 5). To assess the effects of [(PhTe).sub.2] on the cytoskeleton of neural cells and to shed light onto the signaling cascades targeted by the neurotoxicant, we used pharmacological and immunological approaches in which specific enzyme inhibitors, channel blockers, or glutamate antagonists as well as monoclonal antibodies directed to signaling cascades or specific phosphorylation sites let us conclude that [(PhTe).sub.2] interferes with the cell signal transduction misregulating the phosphorylation/dephosphorylation of IFs and disrupting the homeostasis of the cytoskeleton of astrocytes and neurons. Compelling evidence points to a remarkable role of [Ca.sup.2+] mediating these actions secondary to NMDA and L-VDCC activation. In vivo studies have demonstrated that disruption of the cytoskeleton takes part in the deleterious effects of [(PhTe).sub.2] on neural cells culminating with astrogliosis and neuronal death [177, 178]. Also, acute brain slices were useful to further elucidate the molecular basis of the [(PhTe).sub.2] neurotoxicity. In this context, in vivo and ex vivo studies have been important tools to shed light into the molecular mechanisms of the neurotoxicant on the cytoskeleton of neural cells [64,178-183]. More details about the cascade of molecular events triggered by [(PhTe).sub.2] will be presented below.

9. Central Roles of [Ca.sup.2+] and Glutamate Receptors Mediating the Actions of Diphenyl Ditelluride on the Cytoskeleton

Most of the actions of [(PhTe).sub.2] disrupting the homeostasis of the cytoskeleton in neural cells are mediated by high [Ca.sup.2+] levels. Changes in the cytoplasmic free [Ca.sup.2+] concentration constitute one of the main pathways by which information is transferred from extracellular signals received by animal cells to intracellular sites [184-186]. Otherwise, an augmented [Ca.sup.2+] influx through the NMDA receptor or VDCC can be responsible for the activation of lethal metabolic pathways. Different toxins and stress conditions [187-190] have been implicated in the regulation of intracellular [Ca.sup.2+]-dependent processes in cells, and different cell types exhibit a diverse range of transient responses to the same stimulus.

Exposure of tissue slices to [(PhTe).sub.2] triggers the activation of ionotropic and metabotropic glutamate receptors as well as VDCC and the endoplasmic reticulum [Ca.sup.2+] channels. These receptors and channels activate several cellular responses by distinct signaling pathways in a spatiotemporally regulated manner. Metabolism of cyclic nucleotides and membrane phospholipids and activation of different protein kinases and phosphatases, particularly MAPKs, PKC, CaMKII, and protein phosphatase 1 (PP1) as well as endogenous enzymatic regulators, are the key biochemical steps and pathways we have evidenced. Alterations in these key brain mechanisms disrupt the homeostasis of the cytoskeleton and this could explain the neural damage observed following in vivo exposure to [(PhTe).sub.2] [179].

Intracellular [Ca.sup.2+] is one of the crucial signals that modulate the action of [(PhTe).sub.2] in rat brain. This is in line with previous evidence pointing dysregulation of [Ca.sup.2+] homeostasis as an important event in driving different neuropathologies, such as in the expression of the malignant phenotypes [191] and in neurodegenerative conditions [192]. Interestingly, [(PhTe).sub.2] provoked different responses in the cerebral cortex and hippocampus [182], reinforcing that different types of cells can respond in a different way to the same extracellular signal molecule. Taking into account the compelling evidence of its ability in disrupting signaling mechanisms, ditelluride can be used as a tool to induce molecular changes similar to those found in different pathologies of the brain. Consequently, the study of its neurotoxicity can be instrumental to understandnot only thebasis of telluriumtoxicitybut also the role of pathways involved in the neuropathology of different types of brain diseases associated with aging.

Acute brain slices exposed to [(PhTe).sub.2] showed PP1-mediated hypophosphorylation of GFAP and NF subunits in cerebral cortex of 9- and 15-day-old rats but not in hippocampus at this developmental period 182]. Hypophosphorylation was dependent on ionotropic glutamate receptors, L-VDCC, and ryanodine channels. Interestingly, activation of PP1 was modulated by dopamine and cyclic AMP-regulated neuronal phosphoprotein 32 (DARPP-32), an important endogenous [Ca.sup.2+]-mediated inhibitor of PP1 activity. Depending on the site of phosphorylation, DARPP-32 is able to produce opposing biochemical effects, that is, inhibition of PP1 activity or inhibition of protein kinase A (PKA) activity. Phosphorylation of DARPP-32 at Thr34 by PKA constitutes an important mechanism to activate DARPP-32, blocking PP1. Conversely, when pThr34 DARPP-32 is dephosphorylated by protein phosphatase 2B (PP2B), it is itself inhibited, promoting the release of PP1 activity. Moreover, phosphorylation of Thr75DARPP-32 by Cdk-5 inhibits PKA, reinforcing the release of PP1 activity [193] (Figure 4). [(PhTe).sub.2] induced decreased phosphorylation level of DARPP-32 at Thr34 and increased phosphorylation levels of DARPP-32 at Thr75. These findings are compatible with inactivation of PKA, releasing PP1 to dephosphorylate the IFs. It is interesting to note that the complexity of the neurotoxic effect evoked by [(PhTe).sub.2] in Cdk5 is involved in NF hypophosphorylation, rather than hyperphosphorylation, as previously described [194]. Decreased cAMP and PKA catalytic subunit support that [(PhTe).sub.2] disrupted the cytoskeletal associated phosphorylating/dephosphorylating system of neurons and astrocytes through PKA-mediated inactivation of DARPP-32, promoting PP1 release and hypophosphorylation of IF proteins of those neural cells (Figure 4). Buffering the intracellular [Ca.sup.2+] by the [Ca.sup.2+] chelator Bapta-AM showed that it is upstream of cAMP and PKA modulation [182]. During artificial or agonist-induced [Ca.sup.2+] oscillations, Willoughby and Cooper [195] detected fast, periodic changes in type 8 adenylyl cyclase (AC8) with subsequent PKA-mediated phosphodiesterase 4 (PDE4) activity in human embryonic kidney (HEK293) cells. As corollary, it can be concluded that the dynamic complexity of [Ca.sup.2+] signaling includes the ability of [Ca.sup.2+] to regulate other second messengers, such as cAMP. In this context, our results corroborate the role of [Ca.sup.2+] as an upstream effector of [(PhTe).sub.2]-evoked signal on the cytoskeleton, since hypophosphorylation was abolished in the presence of NMDA antagonists (MK-801 and DL-AP5), L-VDCC (verapamil and nifedipine), and endoplasmic reticulum (dantrolene) [Ca.sup.2+] channels [182] (Figure 4).

IF hypophosphorylation is in line with previous evidence showing that protein phosphatases are highly concentrated in the mammalian brain [196-198] and pointing the cytoskeleton as a preferential target of the action of phosphatases in both physiological and pathological conditions [199-201]. Moreover, hypophosphorylation of IF proteins could also be associated with brain damage, since the increased NF packing density correlates with decreased phosphorylation of KSP repeats in the carboxyl-terminal domains of NF-M and NF-H [202].

It is evident that the neurotoxic mechanism of [(PhTe).sub.2] in the cerebral cortex involves the state of phosphorylation of DARPP-32, a modulator of the cAMP pathway previously described to be highly expressed in striatal projection neurons [203]. It is interesting to note that we have previously described [(PhTe).sub.2]-induced hyperphosphorylation in the cerebral cortex of 17-day-old rats ex vivo rather than hypophosphorylation, as observed in the hippocampus [93]. These paradoxical divergent findings provide an interesting insight into the differential susceptibility of cortical IF cytoskeleton to the exposure to this neurotoxicant and could reflect the existence of different vulnerabilities of the cytoskeleton of cortical cells during development based on the temporal maturation mediated by a multitude of developmental processes and signaling pathways [75,204]. However, the exact explanation for the differential effects of [(PhTe).sub.2] on the cytoskeletal protein phosphorylation as a function of postnatal age remains to be clarified. Probably, they are associated with the pathological role of the developmentally regulated glutamate receptors in neural cells within the brain which is dependent on the maturation patterns of glutamate receptor expression [205, 206]. Although the developmentally regulated ontogenetic expression of the glutamate receptors is poorly known, it has been shown that the expression patterns of glutamate receptor subunit genes change during the ontogeny of the brain [207-209]. Distinct regional and temporal patterns of expression of types and subtypes of the glutamate ionotropic receptors during ontogeny [205, 206] may possibly explain the different signaling pathways targeting the cytoskeleton of cortical neural cells during development.

In contrast with cerebral cortex, ex vivo exposure to [(PhTe).sub.2] (100 [micro]M) induced hyperphosphorylation of astrocyte and neuron IFs in acute hippocampal slices of 21-day-old rats. Hyperphosphorylation is partially dependent on L-VDCC, NMDA, and endoplasmic reticulum [Ca.sup.2+] channels. The role of [Ca.sup.2+] as an upstream signal of this effect was demonstrated by specific NMDA antagonists and [Ca.sup.2+] channel blockers as well as extra- and intracellular [Ca.sup.2+] buffering, which totally prevented IF hyperphosphorylation [181] (Figure 5).

The signal evoked by [(PhTe).sub.2] is also transduced through metabotropic glutamate receptors on the plasma membrane leading to the activation of phospholipase C (PLC) which catalyses the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) to produce the intracellular messengers inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 is highly mobile in the cytoplasm and diffuses into the cell interior where it binds to specific receptors on the endoplasmic reticulum. The binding of IP3 changes the conformation of IP3 receptors such that an integral channel is opened. [Ca.sup.2+] stored at high concentrations in the endoplasmic reticulum is released to the cytoplasm. Therefore, high [Ca.sup.2+] levels and DAG directly activate PKCaMII and PCK, resulting in the hyperphosphorylation of Ser-57 in the carboxylterminal tail domain of NF-L. Also, the activation of Erk1/2 and p38MAPK resulted in hyperphosphorylation of KSP repeats of the medium molecular weight NF subunit (NFM). It is noteworthy that PKCaMII and PKC inhibitors (KN-93 and staurosporine, resp.) prevented [(PhTe).sub.2]-induced Erk1/2MAPK and p38MAPK activation as well as hyperphosphorylation of KSP repeats on NF-M, suggesting that PKCaMII and PKC could be upstream of this activation [181]. Interestingly, this effect implies a significant cross-talk among signaling pathways elicited by [(PhTe).sub.2], connecting the glutamate metabotropic cascade with activation of [Ca.sup.2+] channels. The final molecular result is the extensive phosphorylation of amino- and carboxyl-terminal sites on IF proteins [181]. This is in line with the proposal that hyperactivation/deregulation of these kinase cascades may induce aberrant phosphorylation of the cytoskeletal proteins in neurons leading to neural dysfunctions seen in neurodegenerative diseases [210].

10. Diphenyl Ditelluride Disrupts the Cytoskeleton and Provokes Neurodegeneration in Acutely Injected Young Rats

The brain has a prolonged period of postnatal maturation, and myelination is not complete until adolescence [211], which in the rat brain is up to postnatal day 50 [212]. The initial appearance and progressive phosphorylation of NF-M and NF-H in the axons are region-specific and appear to be correlated to synaptogenesis and myelination, as the mature axonal cytoskeleton begins to be established [213,214]. Therefore, it is expected that the deleterious effects of tellurium are preferentially expressed during development, since the intense plasticity underlying the developmental events [215, 216] is dependent on efficient remodeling of the cytoskeleton which, in turn, is dependent on the physiological phosphorylation of the cytoskeletal proteins. Improper developmental plasticity likely impedes the normal information processing in the brain. In line with this, in vivo exposure to [(PhTe).sub.2], in which the neurotoxicant reaches the brain via systemic circulation, provokes aberrant phosphorylation of IF proteins from neural cells by MAPK (Erk, JNK, and p38MAPK) and PKA activities, as demonstrated in the striatum [179] and cerebellum of young rats [64].

According to the ex vivo evidence, the phosphorylating system associated with the cytoskeleton from different brain regions of developing rats also shows different susceptibilities to in vivo [(PhTe).sub.2] exposure. This can be evidenced in cerebral cortex and hippocampus of 15-day-old rats acutely injected with a toxic dose of [(PhTe).sup.2] (0.3 [micro]mol/kg body weight) [20, 180]. Cortical hyperphosphorylation of neuronal and glial IF proteins was an early and persistent event up to 6 days after injection, accompanied by increased levels of GFAP and NF-L. Upregulation of gene expression as well as GFAP and vimentin hyperphosphorylation could be a response to injury and take part in the program of reactive astrogliosis as demonstrated in striatum and cerebellum of [(PhTe).sub.2]-injected rats [64, 179]. Otherwise, in the hippocampus the aberrant phosphorylation was a later response presented only by the astrocyte IFs, without detectable alteration of their levels into the cell, suggesting a milder response [180]. Taking into account the cytoskeletal response evoked by [(PhTe).sub.2], hippocampal astrocytes and neurons showed lower vulnerability than their cortical counterparts. These findings could be related to the differential pathophysiological responses of cortical and hippocampal neurons and astrocytes to the insult. Apparently, hippocampus of rodents is more resistant than cerebral cortex to other neurotoxic insults. This is supported by findings from [217] who described neuropathological changes and tau hyperphosphorylation in the cerebral cortex of adult mice exposed to methyl mercury, but not in the hippocampus.

Under a deleterious process, astrocytes become reactive releasing a wide array of mediators, including pro- and anti-inflammatory cytokines, neurotrophic factors chemokines, complement factors, and reactive oxygen species (ROS), all of which potentially mediate neuroprotective and/or neurotoxic effects [218-220]. In line with this, a strong evidence supports an important role of astrocytes in a more severe cortical than hippocampal damage following the in vivo [(PhTe).sub.2] insult.

The phosphorylation level of IF proteins from acute cortical slices from 18- and 21-day-old rats exposed to [(PhTe).sub.2] was not altered, while IFs of acute cortical slices from younger pups (9 and 15 days old) were hypophosphorylated. In addition, hippocampal IFs were not responsive to the insult until weaning [182]. In a sense, ex vivo and in vivo findings are in agreement, showing that cortical cells are more susceptible to the toxicant than their hippocampal counterparts. On the other hand, these results highlight the relevance of the interplay between glial and neuronal cells to adapt the cellular metabolic response to the insult. The loss of physiological brain connections in brain slices could underlie this response. These findings are in line with the role of astrocytes in determining the vulnerability of neurons to deleterious stimuli [175, 221, 222].

Aberrant phosphorylation of GFAP is associated with injury and pathological conditions. Similarly, abnormal phosphorylation of NFs is associated with neurodegeneration [148, 149, 223, 224]. In neurons, hyperphosphorylated NFs can inhibit their proteolytic breakdown by calpain, a [Ca.sup.2+] activated protease [101, 225]. Abnormally phosphorylated NFs accumulate in the perikarya and the phospho-NF aggregates can thus become cytotoxic by the enduring impairment of axonal transport of NFs [226, 227]. In line with this, kinesin and dynein motor proteins were found to accumulate in NF spheroids in spinal motor neurons and spinal sensory ganglion neurons of chicks injected with beta'-iminodipropionitrile (IDPN) [228], which could impede the transport of components required for axonal maintenance, as demonstrated in a transgenic mouse model of amyotrophic lateral sclerosis [229]. The increased time the NF spent in the cell body is thought to result in further aberrant phosphorylation [230] and may prevent them from entering the axon, resulting in a deleterious feedback loop [147].

Consistent with a critical role of disrupted cytoskeleton in brain damage, MAPK and PKA activation as well as astrogliosis take part in the early responses to the insult with [(PhTe).sub.2] in rat cerebellum [179] and striatum [ 54]. However, the most striking difference between cerebellum and striatum response to [(PhTe).sub.2] is that in cerebellum astrogliosis preceded the apoptotic neuronal death, while in striatum astrogliosis was a later response concomitant with neuronal damage without net neuronal loss, emphasizing the higher vulnerability of the cerebellum to this neurotoxic effect. The different windows of susceptibility leading to activation of MAPK pathway targeting the cytoskeleton in the cerebellum compared with those in the striatum could once more underlie the differential response of these structures to the injury.

Neurodegeneration in [(PhTe).sub.2] rats was also related with inhibited Akt, activated caspase 3, and decreased [[sup.3]H]glutamate uptake, emphasizing a critical role of altered [Ca.sup.2+] levels in this process, since IP3 and ryanodine receptors may be important sensors of disturbed intracellular [Ca.sup.2+] homeostasis [231]. On the basis of our findings, we propose that [(PhTe).sub.2] produced alterations in [Ca.sup.2+] homeostasis and glutamatergic neurotransmission which lead to excitotoxicity and neurodegeneration in the developing rat brain.

Taking into account the great deal of evidence of NF hyperphosphorylation evoked in cerebral cortex, cerebellum, and striatum of [(PhTe).sub.2]-injected rats, it is feasible that this neurotoxicant is not able to provoke demyelination in the CNS, in contrast with peripheral demyelination described in rats [20, 21, 232]. In this context, the specific molecules in myelinating cells that regulate signaling cascades, which in turn modulate the expression and phosphorylation of cytoskeleton elements, have not been fully identified. However, compelling evidence points to a role for myelin-associated proteins modulating expression and phosphorylation of NFs and consequently the axonal caliber [168, 202, 233]. A schematic representation of the in vivo actions of [(PhTe).sub.2] in the brain of young rats is depicted in Figure 6.

11. Gestational and Lactational Toxicity of Diphenyl Ditelluride

There are experimental points of evidence that [(PhTe).sub.2] causes gestational and lactational toxicity [19, 90]. Considering the lipophilic character of this compound, we can suppose that it could cross the placental barrier during pregnancy and be excreted in milk after birth, like other hydrophobic toxicants, such as polychlorinated biphenyls [234]. Thus, the characteristics of solubility of [(PhTe).sub.2] together with the high vulnerability during a period of intense brain development define the high vulnerability of perinatal rat brain as important targets of intoxication with Te.

The immature brain is a much more dynamically active tissue than the mature brain. Its high degree of plasticity and a broad range of potential developmental directions underlie developmental toxicity studies, indicating that maternal toxicity during the pregnancy and/or lactation has been shown to produce adverse effects in offspring [235]. Although the consequences of gestational and lactational exposure to any toxin on brain function are not well understood, exposure to neurotoxic chemicals is of particular concern when it occurs during early development. Fetal and neonatal brain development is characterized by developmental time windows during which certain brain regions or neuron types are specifically sensitive to environmental influences [236] and neurotoxicants [237].

Evidence that the toxic effects of maternal exposure to [(PhTe).sub.2] could be detected in their offspring has been previously reported. High doses of [(PhTe).sub.2] (0.12mg/kg of body weight) can be teratogenic to rat and mice fetuses, causing malformations in fore- and hind-limbs, absent or short tail, subcutaneous blood clots, exophthalmia, hydrocephalus, and presence of exposed brain. However, the mice are less susceptible to toxic effects induced by [(PhTe).sub.2] than the rats, suggesting a different developmental toxicity induced by [(PhTe).sub.2] among species [19, 90].

Stangherlin et al. [22] demonstrated that subchronic exposure to [(PhTe).sub.2] (0.03 mg/kg of body weight), via maternal milk, caused oxidative stress in brain structures of young rats. Theexposureto[(PhTe).sub.2] increased lipid peroxidation and inhibited d-aminolevulinate dehydratase (d-ALA-D), catalase, and superoxide dismutase (SOD) activities in hippocampus and striatum of young rats. Moreover, dam exposure to the same concentration of [(PhTe).sub.2] induced changes in the levels of nonenzymatic defenses in cerebral cortex and striatum of the lactating rats. Supporting the relevance of maternal milk as an important via of toxicity with the [(PhTe).sub.2], exposure of dams to low levels of [(PhTe).sub.2] during the first 14 days of lactation causes neurobehavioral changes of their offspring, which emphasizes the potential neurotoxicity of organic tellurium compounds [21]. Disrupted cytoskeleton could underlie these behavioral impairments since [(PhTe).sub.2] (0.01 mg/kg of body weight) evoked aberrantly phosphorylated astrocyte and neuron IFs observed on PND 15 and 21 in striatum and cerebellum of rats. On the other hand, exposure to [(PhTe).sub.2] via maternal milk provoked hyperphosphorylation of IF protein in the hippocampus only on PND 21 and 30 (unpublished results), evidencing a latter effect in this brain structure. This is in line with ex vivo and in vivo studies reporting disrupted phosphorylation level of hippocampal IFs in 21-day-old rats [178, 183]. These findings could be related with the differential pathophysiological responses of the different structures to the insult according to their critical proliferative period [212].

The effect of [(PhTe).sub.2] was spatiotemporally regulated, and the posttraductional mechanisms regulating the cytoskeleton from striatum and cerebellum in younger pups are more susceptible to the action of the neurotoxicant than in older ones. In fact, suckling rats can be considered extremely susceptible to [(PhTe).sub.2]-induced neurotoxicity, since the dose of [(PhTe).sub.2] given to dams was extremely low. As a corollary, the offspring of [(PhTe).sub.2]-treated dams is expected to be exposed to telluride levels much lower than those given to their mothers.

Further evidence of the great susceptibility of pups to the toxic effects of [(PhTe).sub.2] via maternal milk comes from the previously reported inhibition of glutamate uptake and Na+/K+ATPase activity in the brain of pups from exposed dams [22]. Moreover, MAPK and PKA pathways are activated in neural cells of striatum and cerebellum of the offspring [183]. This could be related to the disruption of the cytoskeleton observed in these pups. Interestingly, the kinase activities as well as the phosphorylating level of the IF proteins are increased in PND 15 and 21 and returned to control levels in older pups. This could be explained by adaptative mechanisms overriding the prolonged exposure to the toxicant; however, this point remains to be clarified. Also, we could presume that altered glutamate uptake and [Na.sup.+]/[K.sup.+] ATPase activity as well as disrupted cytoskeleton could be involved in the neurobehavioral changes of the offspring.

Taking into account the whole evidence that, following maternal exposure, [(PhTe).sub.2] reaches the brain of their offspring via systemic circulation, we are tempted to propose that results from the animal model could mimic the risk of a potential [(PhTe).sub.2] exposure of pregnant or lactating women to their babies. However, little information about human intoxication with [(PhTe).sub.2] during pregnancy and lactation is available in the literature and further efforts will be necessary to understand the pathology of this compound.

12. Concluding Remarks

The major questions concerning the [(PhTe).sub.2] toxicity that remain posed relate to the mechanisms that underlie their actions in the CNS. To address this question, we have focused our efforts on the actions of this neurotoxicant targeting the endogenous phosphorylating system associated with the cytoskeleton of neural cells of young rats. It is always expected that the deleterious effects of a toxin are preferentially expressed during development, since the intense plasticity underlying the developmental events [215, 216] is dependent on efficient remodeling of the cytoskeleton which, in turn, is dependent on the physiological phosphorylation of the cytoskeletal proteins. Improper developmental plasticity likely impedes information processing in the brain.

Compelling evidence from our group supports that IF proteins could be crucial in mediating spatiotemporal responses to [(PhTe).sub.2] in neural cells of rats. Central to its function is its dynamic phosphorylation and defects in the capacity to maintain the homeostasis of IF phosphorylation would probably have detrimental effects on cell function. These actions are complex, and integrated processes carefully and precisely orchestrated by the cell through membrane receptors and channels are able to activate diverse signal transduction pathways misregulating the homeostasis of the cytoskeleton. It is remarkable that [Ca.sup.2+]-mediated mechanisms were shown to play a central role in these membraneinitiated mechanisms. It is presumed that aberrantly phosphorylated/dephosphorylated IF proteins may interfere with neural cell structure and function which is associated with neurodegeneration in young animals. Further studies on membrane receptors and their downstream events might provide us with new insights into the molecular basis of the mechanisms triggered by the toxicant in brain. Although cell signaling transduction of [(PhTe).sub.2] does not have necessarily the same mechanisms in different brain regions, the [Ca.sup.2+]-initiated events highlight a role for this neurotoxicant as a disruptor of the cytoskeleton.

Taking into account the relevance of the signaling mechanisms targeting the cytoskeleton during early postnatal brain development, we presume that the spatiotemporal misregulation of the homeostasis of the cytoskeleton we evidenced can probably contribute to the deleterious action of [(PhTe).sub.2] on the developing brain, a fact that might explain at least in part the neurotoxicity of this compound; however, these consequences need further investigation. One aspect that needs further investigation is the effect of inorganic tellurium on IF phosphorylation. This is particularly relevant in view of the increased industrial use of tellurium in electronic devices.

We think that our studies in injected rats or in acute brain slices have made important contributions to our understanding of [(PhTe).sub.2]-mediated injury. These studies provide the opportunity to examine cellular, molecular, and morphological changes after exposure to the neurotoxicant. However, extrapolation of conclusions from animal data to human beings must be done with caution. Of particular experimental importance, the study of [(PhTe).sub.2] neurotoxicity can be instrumental to understand not only the basis of tellurium toxicity but also the role of pathways involved in the neuropathology of different types of brain diseases associated with neurodegeneration and aging.

Conflict of Interests

The authors declare that they have no conflict of interests regarding the publication of this paper.


[1] A. J. Larner, "Biological effects of tellurium: a review," Trace Elements and Electrocytes, vol. 12, no. 1, pp. 26-31, 1995.

[2] N. Petragnani and H. A. Stefani, "Advances in organic tellurium chemistry," Tetrahedron, vol. 61, no. 7, pp. 1613-1679, 2005.

[3] G. Zeni, D. S. Ludtke, R. B. Panatieri, and A. L. Braga, "Vinylic tellurides: from preparation to their applicability in organic synthesis," Chemical Reviews, vol. 106, no. 3, pp. 1032-1076, 2006.

[4] J. V Comasseto and A. A. Dos Santos, "Organotellurides as precursors of reactive organometallics," Phosphorus, Sulfur and Silicon and the Related Elements, vol. 183, no. 4, pp. 939-947, 2008.

[5] J. L. Princival, A. A. Dos Santos, and J. V Comasseto, "Reactive organometallics from organotellurides: application in organic synthesis," Journal of the Brazilian Chemical Society, vol. 21, no. 11, pp. 2042-2054, 2010.

[6] R. S. Ferrarini, A. A. Dos Santos, and J. V Comasseto, "Tellurium in organic synthesis: a general approach to buteno- and butanolides," Tetrahedron, vol. 68, no. 51, pp. 10601-10610, 2012.

[7] R. Hardman, "A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors," Environmental Health Perspectives, vol. 114, no. 2, pp. 165-172, 2006.

[8] S. J. Klaine, P. J. J. Alvarez, G. E. Batley et al., "Nanomaterials in the environment: behavior, fate, bioavailability, and effects," Environmental Toxicology and Chemistry, vol. 27, no. 9, pp. 1825-1851, 2008.

[9] Y. Ogra, "Toxicometallomics for research on the toxicology of exotic metalloids based on speciation studies," Analytical Sciences, vol. 25, no. 10, pp. 1189-1195, 2009.

[10] E. Dopp, L. M. Hartmann, A.-M. Florea, A. W Rettenmeier, and A. V. Hirner, "Environmental distribution, analysis, and toxicity of organometal(loid) compounds," Critical Reviews in Toxicology, vol. 34, no. 3, pp. 301-333, 2004.

[11] J. Lovric, S. J. Cho, F. M. Winnik, and D. Maysinger, "Unmodified cadmium telluride quantum dots induce reactive oxygen species formation leading to multiple organelle damage and cell death," Chemistry and Biology, vol. 12, no. 11, pp. 1227-1234, 2005.

[12] P. Babula, V Adam, R. Opatrilova, J. Zehnalek, L. Havel, and R. Kizek, "Uncommon heavy metals, metalloids and their plant toxicity: a review," Environmental Chemistry Letters, vol. 6, no. 4, pp. 189-213, 2008.

[13] F. Gagne, J. Auclair, P. Turcotte et al., "Ecotoxicity of CdTe quantum dots to freshwater mussels: impacts on immune system, oxidative stress and genotoxicity," Aquatic Toxicology, vol. 86, no. 3, pp. 333-340, 2008.

[14] A. Taylor, "Biochemistry of tellurium," Biological Trace Element Research, vol. 55, no. 3, pp. 231-239, 1996.

[15] H. Wen, J. Zhong, B. Shen et al., "Comparative study of the cytotoxicity of the nanosized and microsized tellurium powders on HeLa cells," Frontiers in Biology, vol. 8, no. 4, pp. 444-450, 2013.

[16] T. G. Chasteen and R. Bentley, "Biomethylation of selenium and tellurium: microorganisms and plants," Chemical Reviews, vol. 103, no. 1, pp. 1-25, 2003.

[17] C. W. Nogueira, G. Zeni, and J. B. T. Rocha, "Organoselenium and organotellurium compounds: toxicology and pharmacology," Chemical Reviews, vol. 104, no. 12, pp. 6255-6285, 2004.

[18] V B. Brito, J. B. T. Rocha, V Folmer, and F. Erthal, "Diphenyl diselenide and diphenyl ditelluride increase the latency for 4aminopyridine- induced chemical seizure and prevent death in mice," Acta Biochimica Polonica, vol. 56, no. 1, pp. 125-134, 2009.

[19] E. C. Stangherlin, A. M. Favero, G. Zeni, J. B. T Rocha, and C. W. Nogueira, "Teratogenic vulnerability of Wistar rats to diphenyl ditelluride," Toxicology, vol. 207, no. 2, pp. 231-239, 2005.

[20] E. C. Stangherlin, A. M. Favero, S. N. Weis, G. Zeni, J. B. T Rocha, and C. W Nogueira, "Assessment of reproductive toxicity in male rats following acute and sub-chronic exposures to diphenyl diselenide and diphenyl ditelluride," Food and Chemical Toxicology, vol. 44, no. 5, pp. 662-669, 2006.

[21] E. C. Stangherlin, A. M. Favero, G. Zeni, J. B. T Rocha, and C. W. Nogueira, "Exposure of mothers to diphenyl ditelluride during the suckling period changes behavioral tendencies in their offspring," Brain Research Bulletin, vol. 69, no. 3, pp. 311-317, 2006.

[22] E. C. Stangherlin, A. P. Ardais, J. B. T Rocha, and C. W. Nogueira, "Exposure to diphenyl ditelluride, via maternal milk, causes oxidative stress in cerebral cortex, hippocampus and striatum of young rats," Archives of Toxicology, vol. 83, no. 5, pp. 485-491, 2009.

[23] J. I. Rossato, L. A. Ketzer, F. B. Centuriao et al., "Antioxidant properties of new chalcogenides against lipid peroxidation in rat brain," Neurochemical Research, vol. 27, no. 4, pp. 297-303, 2002.

[24] D. S. Avila, A. Benedetto, C. Au et al., "Organotellurium and organoselenium compounds attenuate Mn-induced toxicity in Caenorhabditis elegans by preventing oxidative stress," Free Radical Biology and Medicine, vol. 52, no. 9, pp. 1903-1910, 2012.

[25] S. G. Wollenhaupt, A. T Soares, W. G. Salgueiro et al., "Seleno-and Telluro-xylofuranosides attenuate Mn-induced toxicity in C. elegans via the DAF-16/FOXO pathway," Food and Chemical Toxicology, vol. 1, no. 64, pp. 192-199, 2013.

[26] D. S. de Avila, M. C. Beque, V Folmer et al., "Diethyl 2-phenyl-2 tellurophenyl vinylphosphonate: an organotellurium compound with low toxicity," Toxicology, vol. 224, no. 1-2, pp. 100-107, 2006.

[27] D. S. Avila, P. Gubert, C. L. Dalla Corte et al., "A biochemical and toxicological study with diethyl 2-phenyl-2-tellurophenyl vinylphosphonate in a sub-chronic intraperitoneal treatment in mice," Life Sciences, vol. 80, no. 20, pp. 1865-1872, 2007

[28] D. S. Avila, P. Gubert, A. Palma et al., "An organotellurium compound with antioxidant activity against excitotoxic agents without neurotoxic effects in brain of rats," Brain Research Bulletin, vol. 76, no. 1-2, pp. 114-123, 2008.

[29] V P. P. Schiar, D. B. dos Santos, M. W. Paixao, C. W. Nogueira, J. B. T. Rocha, and G. Zeni, "Human erythrocyte hemolysis induced by selenium and tellurium compounds increased by GSH or glucose: a possible involvement of reactive oxygen species," Chemico-Biological Interactions, vol. 177, no. 1, pp. 2833, 2009.

[30] L. A. Ba, M. Doring, V. Jamier, and C. Jacob, "Tellurium: an element with great biological potency and potential," Organic and Biomolecular Chemistry, vol. 8, no. 19, pp. 4203-4216, 2010.

[31] V. Jamier, L. A. Ba, and C. Jacob, "Selenium- and tellurium-containing multifunctional redox agents as biochemical redox modulators with selective cytotoxicity," Chemistry, vol. 16, no. 36, pp. 10920-10928, 2010.

[32] R. L. O. R. Cunha, I. E. Gouvea, and L. Juliano, "A glimpse on biological activities of tellurium compounds," Anais da Academia Brasileira de Ciencias, vol. 81, no. 3, pp. 393-407, 2009.

[33] I. A. S. Pimentel, C. D. S. Paladi, S. Katz, W. A. D. S. Judice, R. L. O. R. Cunha, and C. L. Barbieri, "In vitro and in vivo activity of an organic tellurium compound on leishmania (Leishmania) chagasi," PLoS ONE, vol. 7, no. 11, Article ID e48780, 2012.

[34] B. Sredni, R. R. Caspi, A. Klein et al., "A new immunomodulating compound (AS-101) with potential therapeutic application," Nature, vol. 330, no. 6144, pp. 173-176, 1987

[35] E. Okun, T. V. Arumugam, S.-C. Tang et al., "The organotellurium compound ammonium trichloro(dioxoethylene-0,0') tellurate enhances neuronal survival and improves functional outcome in an ischemic stroke model in mice," Journal of Neurochemistry, vol. 102, no. 4, pp. 1232-1241, 2007

[36] G. M. Frei, M. Kremer, K.-M. Hanschmann et al., "Antitumour effects in mycosis fungoides of the immunomodulatory, tellurium-based compound, AS101," British Journal of Dermatology, vol. 158, no. 3, pp. 578-586, 2008.

[37] Y. Kalechman and B. Sredni, "Differential effect of the immunomodulator AS101 on B7-1 and B7-2 costimulatory molecules: role in the antitumoral effects of AS101," Journal of Immunology, vol. 157, no. 2, pp. 589-597, 1996.

[38] M. Israeli, B. Sredni, E. Mor, C. Zakai, B. Tadmor, and T Klein, "The immune-modulator AS101 reduces anti-HLA antibodies in sera of sensitized patients: a structural approach," International Immunopharmacology, vol. 13, no. 4, pp. 483-489, 2012.

[39] B. Sredni, R. Gal, I. J. Cohen et al., "Hair growth induction by the Tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes and ras-dependent up-regulation of KGF expression," The FASEB Journal, vol. 18, no. 2, pp. 400-402, 2004.

[40] K. Iwase, T. Tatsuishi, Y. Nishimura et al., "Cytometric analysis of adverse action of diphenyl ditelluride on rat thymocytes: cell shrinkage as a cytotoxic parameter," Environmental Toxicology, vol. 19, no. 6, pp. 614-619, 2004.

[41] B. L. Sailer, N. Liles, S. Dickerson, S. Sumners, and T. G. Chasteen, "Organotellurium compound toxicity in a promyelocytic cell line compared to non-tellurium-containing organic analog," Toxicology in Vitro, vol. 18, no. 4, pp. 475-482, 2004.

[42] B. L. Sailer, N. Liles, S. Dickerson, and T. G. Chasteen, "Cytometric determination of novel organotellurium compound toxicity in apromyelocytic (HL-60) cell line," Archives of Toxicology, vol. 77, no. 1, pp. 30-36, 2003.

[43] S. Roy and D. Hardej, "Tellurium tetrachloride and diphenyl ditelluride cause cytotoxicity in rat hippocampal astrocytes," Food and Chemical Toxicology, vol. 49, no. 10, pp. 2564-2574, 2011.

[44] D. S. Avila, D. Colle, P. Gubert et al., "A possible neuroprotective action of a vinylic telluride against Mn-induced neurotoxicity," Toxicological Sciences, vol. 115, no. 1, pp. 194-201, 2010.

[45] D. Caeran Bueno, D. F. Meinerz, J. Allebrandt et al., "Cytotoxicity and genotoxicity evaluation of organochalcogens in human leucocytes: a comparative study between ebselen, diphenyl diselenide, and diphenyl ditelluride," BioMed Research International, vol. 2013, Article ID 537279, 6 pages, 2013.

[46] D. F. Meinerz, J. Allebrandt, D. O. C. Mariano et al., "Differential genotoxicity of diphenyl diselenide [(PhSe).sub.2] and diphenyl ditelluride [(PhTe).sub.2] ," PeerJ, vol. 2, article e290, 2014.

[47] J. F. Goodrum, "Role of organotellurium species in tellurium neuropathy," Neurochemical Research, vol. 23, no. 10, pp. 1313-1319, 1998.

[48] J. F. Goodrum, T S. Earnhardt, N. D. Goines, and T. W. Bouldin, "Lipid droplets in Schwann cells during tellurium neuropathy are derived from newly synthesized lipid," Journal of Neurochemistry, vol. 55, no. 6, pp. 1928-1932, 1990.

[49] G. J. Harry, J. F. Goodrum, T. W. Bouldin, M. Wagner-Recio, A. D. Toews, and P. Morell, "Tellurium-induced neuropathy: metabolic alterations associated with demyelination and remyelination in rat sciatic nerve," Journal of Neurochemistry, vol. 52, no. 3, pp. 938-945, 1989.

[50] J. H. Keall, N. H. Martin, and R. E. Tunbridge, "A report of three cases of accidental poisoning by sodium tellurite," British Journal of Industrial Medicine, vol. 3, pp. 175-176, 1946.

[51] A. Albeck, H. Weitman, B. Sredni, and M. Albeck, "Tellurium compounds: selective inhibition of cysteine proteases and model reaction with thiols," Inorganic Chemistry, vol. 37, no. 8, pp. 1704-1712, 1998.

[52] R. J. Turner, J. H. Weiner, and D. E. Taylor, "Tellurite-mediated thiol oxidation in Escherichia coli," Microbiology, vol. 145, no. 9, pp. 2549-2557, 1999.

[53] R. J. Turner, Y. Aharonowitz, J. H. Weiner, and D. E. Taylor, "Glutathione is a target in tellurite toxicity and is protected by tellurite resistance determinants in Escherichia coli" Canadian Journal of Microbiology, vol. 47, no. 1, pp. 33-40, 2001.

[54] J. M. Perez, I. L. Calderon, F. A. Arenas et al., "Bacterial toxicity of potassium tellurite: unveiling an ancient enigma," PLoS ONE, vol. 2, no. 2, article e211, 2007.

[55] T G. Chasteen, D. E. Fuentes, J. C. Tantalen, and C. C. Vosquez, "Tellurite: history, oxidative stress, and molecular mechanisms of resistance: review article," FEMS Microbiology Reviews, vol. 33, no. 4, pp. 820-832, 2009.

[56] J. M. Sandoval, P. Leveque, B. Gallez, C. C. Vosquez, and P. B. Calderon, "Tellurite-induced oxidative stress leads to cell death of murine hepatocarcinoma cells," BioMetals, vol. 23, no. 4, pp. 623-632, 2010.

[57] B. Comparsi, D. F. Meinerz, J. L. Franco et al., "Diphenyl ditelluride targets brain selenoproteins in vivo: inhibition of cerebral thioredoxin reductase and glutathione peroxidase in mice after acute exposure," Molecular and Cellular Biochemistry, vol. 370, no. 1-2, pp. 173-182, 2012.

[58] M. McNaughton, L. Engman, A. Birmingham, G. Powis, and I. A. Cotgreave, "Cyclodextrin-derived diorganyl tellurides as glutathione peroxidase mimics and inhibitors of thioredoxin reductase and cancer cell growth," Journal of Medicinal Chemistry, vol. 47, no. 1, pp. 233-239, 2004.

[59] L. Engman, I. Cotgreave, M. Angulo, C. W. Taylor, G. D. Paine-Murrieta, and G. Powis, "Diaryl chalcogenides as selective inhibitors of thioredoxin reductase and potential antitumor agents," Anticancer Research, vol. 17, no. 6, pp. 4599-4605, 1997

[60] L. Engman, T. Kanda, A. Gallegos, R. Williams, and G. Powis, "Water-soluble organotellurium compounds inhibit thioredoxin reductase and the growth of human cancer cells," Anti-Cancer Drug Design, vol. 15, no. 5, pp. 323-330, 2000.

[61] L. Engman, N. Al-Maharik, M. McNaughton, A. Birmingham, and G. Powis, "Thioredoxin reductase and cancer cell growth inhibition by organotellurium compounds that could be selectively incorporated into tumor cells," Bioorganic and Medicinal Chemistry, vol. 11, no. 23, pp. 5091-5100, 2003.

[62] P. Garberg, L. Engman, V. Tolmachev, H. Lundqvist, R. G. Gerdes, and I. A. Cotgreave, "Binding of tellurium to hepatocellular selenoproteins during incubation with inorganic tellurite: consequences for the activity of selenium-dependent glutathione peroxidase," International Journal of Biochemistry and Cell Biology, vol. 31, no. 2, pp. 291-301, 1999.

[63] M. Rooseboom, N. P. E. Vermeulen, F. Durgut, and J. N. M. Commandeur, "Comparative study on the bioactivation mechanisms and cytotoxicity of Te-phenyl-L-tellurocysteine, Se-Phenyl-L-selenocysteine, and S-Phenyl-L-cysteine," Chemical Research in Toxicology, vol. 15, no. 12, pp. 1610-1618, 2002.

[64] L. Heimfarth, S. O. Loureiro, M. F. Dutra et al., "Disrupted cytoskeletal homeostasis, astrogliosis and apoptotic cell death in the cerebellum of preweaning rats injected with diphenyl ditelluride," NeuroToxicology, vol. 34, no. 1, pp. 175-188, 2013.

[65] T W. Bouldin, G. Samsa, T. S. Earnhardt, and M. R. Krigman, "Schwann cell vulnerability to demyelination is associated with internodal length in tellurium neuropathy," Journal of Neuropathology and Experimental Neurology, vol. 47, no. 1, pp. 41-47, 1988.

[66] M. Wagner, A. D. Toews, and P. Morell, "Tellurite specifically affects squalene epoxidase: investigations examining the mechanism oftellurium-induced neuropathy," Journal of Neurochemistry, vol. 64, no. 5, pp. 2169-2176, 1995.

[67] B. P. Laden and T. D. Porter, "Inhibition of human squalene monooxygenase by tellurium compounds: evidence of interaction with vicinal sulfhydryls," Journal of Lipid Research, vol. 42, no. 2, pp. 235-240, 2001.

[68] R. C. Srivastava, R. Srivastava, T. N. Srivastava, and S. P. Jain, "Effect of organo-tellurium compounds on the enzymatic alterations in rats," Toxicology Letters, vol. 16, no. 3-4, pp. 311-316, 1983.

[69] E. N. Maciel, R. C. Bolzan, A. L. Braga, and J. B. T. Rocha, "Diphenyl diselenide and diphenyl ditelluride differentially affect d-aminolevulinate dehydratase from liver, kidney, and brain of mice," Journal of Biochemical and Molecular Toxicology, vol. 14, no. 6, pp. 310-319, 2000.

[70] N. B. V. Barbosa, J. B. T. Rocha, G. Zeni, T. Emanuelli, M. C. Beque, and A. L. Braga, "Effect of organic forms of selenium on d-aminolevulinate dehydratase from liver, kidney, and brain of adult rats," Toxicology and Applied Pharmacology, vol. 149, no. 2, pp. 243-253, 1998.

[71] R. B. de Andrade, T. Gemelli, R. B. Guerra, C. Funchal, and C. M. Duval Wannmacher, "Inhibition of creatine kinase activity by 3-butyl-1-phenyl-2-(phenyltelluro) oct-en-1-one in the cerebral cortex and cerebellum of young rats," Journal of Applied Toxicology, vol. 30, no. 6, pp. 611-616, 2010.

[72] R. B. de Andrade, T. Gemelli, R. B. Guerra, C. Funchal, and C. M. D. Wannmacher, "Kinetic studies on the inhibition of creatine kinase activity by 3-butyl-1-phenyl-2-(phenyltelluro)octen-1-one in the cerebral cortex of rats," Food and Chemical Toxicology, vol. 50, no. 10, pp. 3468-3474, 2012.

[73] C. Funchal, R. B. de Andrade, E. Turcatel, R. B. Guerra, C. M. D. Wannmacher, and R. Gomez, "Acute treatment with the organochalcogen 3-butyl-1-phenyl-2-(phenyltelluro)oct-en-1-one produces behavioral changes and inhibition of creatine kinase activity in the brain of rats," International Journal of Developmental Neuroscience, vol. 29, no. 8, pp. 903-907, 2011.

[74] I. L. Calderon, A. O. Elias, E. L. Fuentes et al., "Tellurite-mediated disabling of [4Fe-4S] clusters of Escherichia coli dehydratases," Microbiology, vol. 155, no. 6, pp. 1840-1846, 2009.

[75] D. Rice and S. Barone Jr., "Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models," Environmental Health Perspectives, vol. 108, supplement 3, pp. 511-533, 2000.

[76] M. Farina, J. B. T Rocha, and M. Aschner, "Mechanisms of methylmercury-induced neurotoxicity: evidence from experimental studies," Life Sciences, vol. 89, no. 15-16, pp. 555-563, 2011.

[77] P. J. Morgane, R. Austin-LaFrance, J. Bronzino et al., "Prenatal malnutrition and development of the brain," Neuroscience and Biobehavioral Reviews, vol. 17, no. 1, pp. 91-128, 1993.

[78] W. F. Agnew, F. M. Fauvre, and P. H. Pudenz, "Tellurium hydrocephalus: distribution of tellurium-127m between maternal, fetal, and neonatal tissues of the rat," Experimental Neurology, vol. 21, no. 1, pp. 120-131, 1968.

[79] W. F. Agnew and E. Curry, "Period of teratogenic vulnerability of rat embryo to induction of hydrocephalus by tellurium," Experientia, vol. 28, no. 12, pp. 1444-1445, 1972.

[80] S. Duckett, "The morphology of tellurium-induced hydrocephalus," Experimental Neurology, vol. 31, no. 1, pp. 1-16, 1971.

[81] E. M. Johnson, M. S. Christian, A. M. Hoberman, C. J. deMarco, R. Kilpper, and R. Mermelstein, "Developmental toxicology investigation of tellurium," Fundamental and Applied Toxicology, vol. 11, no. 4, pp. 691-702, 1988.

[82] E. N. Maciel, Efeito do tratamento com diseleneto de difenila e ditelureto de difenila sobre a delta aminolevulinato desidratase de figado, rim e cerebro de camundongos adultos [Dissertacao], Universidade Federal do Rio Grande do Sul, Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior. Orientador: Joao Batista Teixeira da Rocha, 2000.

[83] S. Duckett and R. White, "Cerebral lipofuscinosis induced with tellurium: electron dispersive X ray spectrophotometry analysis," Brain Research, vol. 73, no. 2, pp. 205-214, 1974.

[84] J. B. T. Rocha, R. A. Saraiva, S. C. Garcia, F. S. Gravina, and C. W. Nogueira, "Aminolevulinate dehydratase (d-ALA-D) as marker protein of intoxication with metals and other prooxidant situations," Toxicology Research, vol. 1, no. 2, pp. 85-102, 2012.

[85] A. Nyska, T. Waner, M. Pirak, M. Albeck, and B. Sredni, "Toxicity study in rats of a tellurium based immunomodulating drug, AS-101: a potential drug for AIDS and cancer patients," Archives of Toxicology, vol. 63, no. 5, pp. 386-393, 1989.

[86] L. Orian and S. Toppo, "Organochalcogen peroxidase mimetics as potential drugs: a long story of a promise still unfulfilled," Free Radical Biology and Medicine, vol. 66, pp. 65-75, 2014.

[87] M. C. Yarema and S. C. Curry, "Acute tellurium toxicity from ingestion of metal-oxidizing solutions," Pediatrics, vol. 116, no. 2, pp. e319-e321, 2005.

[88] E. S. Blackadder and W. G. Manderson, "Occupational absorption of tellurium: a report of two cases," British Journal of Industrial Medicine, vol. 32, no. 1, pp. 59-61, 1975.

[89] C. J. Berriault and N. E. Lightfoot, "Occupational tellurium exposure and garlic odour," Occupational Medicine, vol. 61, no. 2, pp. 132-135, 2011.

[90] S. S. Roman, A. Nava, A. M. Favero et al., "Diphenyl ditelluride effect on embryo/fetal development in mice: interspecies differences," Toxicology, vol. 231, no. 2-3, pp. 243-249, 2007

[91] S. Pinton, C. Luchese, E. C. Stangherlin, S. S. Roman, and C. W. Nogueira, "Diphenyl ditelluride induces neurotoxicity and impairment of developmental behavioral in rat pups," Journal of the Brazilian Chemical Society, vol. 21, no. 11, pp. 2130-2137, 2010.

[92] M. B. Moretto, C. Funchal, G. Zeni, R. Pessoa-Pureur, and J. B. T. Rocha, "Selenium compounds prevent the effects of methylmercury on the in vitro phosphorylation of cytoskeletal proteins in cerebral cortex of young rats," Toxicological Sciences, vol. 85, no. 1, pp. 639-646, 2005.

[93] M. B. Moretto, C. Funchal, G. Zeni, J. B. T Rocha, and R. PessoaPureur, "Organoselenium compounds prevent hyperphosphorylation of cytoskeletal proteins induced by the neurotoxic agent diphenyl ditelluride in cerebral cortex of young rats," Toxicology, vol. 210, no. 2-3, pp. 213-222, 2005.

[94] C. S. Clemen, H. Herrmann, S. V. Strelkov, and R. Schroder, "Desminopathies: pathology and mechanisms," Acta Neuropathologica, vol. 125, no. 1, pp. 47-75, 2013.

[95] H. Herrmann and U. Aebi, "Intermediate filaments and their associates: multi-talented structural elements specifying cytoarchitecture and cytodynamics," Current Opinion in Cell Biology, vol. 12, no. 1, pp. 79-90, 2000.

[96] S. Kim and P A. Coulombe, "Intermediate filament scaffolds fulfill mechanical, organizational, and signaling functions in the cytoplasm," Genes and Development, vol. 21, no. 13, pp. 1581-1597, 2007.

[97] Z. Xu, D. L.-Y. Dong, and D. W. Cleveland, "Neuronal intermediate filaments: new progress on an old subject," Current Opinion in Neurobiology, vol. 4, no. 5, pp. 655-661, 1994.

[98] M. K. Lee and D. W. Cleveland, "Neuronal intermediate filaments," Annual Review of Neuroscience, vol. 19, pp. 187-217, 1996.

[99] R. B. Wuerker and J. B. Kirkpatrick, "Neuronal microtubules, neurofilaments, and microfilaments," International Review of Cytology, vol. 33, pp. 45-75, 1972.

[100] N. Geisler, J. Vandekerckhove, and K. Weber, "Location and sequence characterization of the major phosphorylation sites of the high molecular mass neurofilament proteins M and H," FEBS Letters, vol. 221, no. 2, pp. 403-407, 1987

[101] M. E. Goldstein, N. H. Sternberger, and L. A. Sternberger, "Phosphorylation protects neurofilaments against proteolysis," Journal of Neuroimmunology, vol. 14, no. 2, pp. 149-160, 1987

[102] H. C. Pant, "Neurofilament phosphorylation," Biochemistry and Cell Biology, vol. 73, no. 9-10, pp. 575-592, 1995.

[103] P N. Hoffman, D. W. Cleveland, J. W. Griffin, P W. Landes,

N. J. Cowan, and D. L. Price, "Neurofilament gene expression: a major determinant of axonal caliber," Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 10, pp. 3472-3476, 1987.

[104] S.-T Hsieh, G. J. Kidd, T. O. Crawford et al., "Regional modulation of neurofilament organization by myelination in normal axons," Journal of Neuroscience, vol. 14, no. 11, pp. 6392-6401, 1994.

[105] R. A. Nixon, P. A. Paskevich, R. K. Sihag, and C. Y. Thayer, "Phosphorylation on carboxyl terminus domains of neurofilament proteins in retinal ganglion cell neurons in vivo: influences on regional neurofilament accumulation, interneurofilament spacing, and axon caliber," Journal of Cell Biology, vol. 126, no. 4, pp. 1031-1046, 1994.

[106] S. M. de Waegh and S. T Brady, "Local control of axonal properties by Schwann cells: neurofilaments and axonal transport in homologous and heterologous nerve grafts," Journal of Neuroscience Research, vol. 30, no. 1, pp. 201-212, 1991.

[107] J. S. Cole, A. Messing, J. Q. Trojanowski, and V. M.-Y. Lee, "Modulation of axon diameter and neurofilaments by hypomyelinating Schwann cells in transgenic mice," Journal of Neuroscience, vol. 14, no. 11, pp. 6956-6966, 1994.

[108] S. M. Dashiell, S. L. Tanner, H. C. Pant, and R. H. Quarles, "Myelin-associated glycoprotein modulates expression and phosphorylation of neuronal cytoskeletal elements and their associated kinases," Journal of Neurochemistry, vol. 81, no. 6, pp. 1263-1272, 2002.

[109] S. T Brady, "Neurofilaments run sprints not marathons," Nature Cell Biology, vol. 2, no. 3, pp. E43-E45, 2000.

[110] R. A. Nixon, "The slow axonal transport of cytoskeletal proteins," Current Opinion in Cell Biology, vol. 10, no. 1, pp. 87-92, 1998.

[111] J. V. Shah, L. A. Flanagan, P. A. Janmey, and J.-F. Leterrier, "Bidirectional translocation of neurofilaments along microtubules mediated in part by dynein/dynactin," Molecular Biology of the Cell, vol. 11, no. 10, pp. 3495-3508, 2000.

[112] J. Motil, W. K.-H. Chan, M. Dubey et al., "Dynein mediates retrograde neurofilament transport within axons and anterograde delivery of NFs from perikarya into axons: regulation by multiple phosphorylation events," Cell Motility and the Cytoskeleton, vol. 63, no. 5, pp. 266-286, 2006.

[113] J. Middeldorp and E. M. Hol, "GFAP in health and disease," Progress in Neurobiology, vol. 93, no. 3, pp. 421-443, 2011.

[114] I. Allaman, M. Belanger, and P. J. Magistretti, "Astrocyte-neuron metabolic relationships: for better and for worse," Trends in Neurosciences, vol. 34, no. 2, pp. 76-87, 2011.

[115] F. L. Cardoso, D. Brites, and M. A. Brito, "Looking at the blood-brain barrier: molecular anatomy and possible investigation approaches," Brain Research Reviews, vol. 64, no. 2, pp. 328-363, 2010.

[116] A. Zamoner and R. Pessoa-Pureur, "Nongenomic actions of thyroid hormones: every why has a wherefore," Immunology, Endocrine and MetabolicAgents in Medicinal Chemistry, vol. 11, no. 3, pp. 165-178, 2011.

[117] D. A. Figlewicz, A. Krizus, M. G. Martinoli et al., "Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis," Human Molecular Genetics, vol. 3, no. 10, pp. 1757-1761, 1994.

[118] E. Arbustini, M. Pasotti, A. Pilotto et al., "Desmin accumulation restrictive cardiomyopathy and atrioventricular block associated with desmin gene defects," European Journal of Heart Failure, vol. 8, no. 5, pp. 477-483, 2006.

[119] G. M. Fabrizi, T. Cavallaro, C. Angiari et al., "Giant axon and neurofilament accumulation in Charcot-Marie-Tooth disease type 2E," Neurology, vol. 62, no. 8, pp. 1429-1431, 2004.

[120] L. Hertel, "Herpesviruses and intermediate filaments: close encounters with the third type," Viruses, vol. 3, no. 7, pp. 10151040, 2011.

[121] M. B. Delisle andS. Carpenter, "Neurofibrillary axonal swellings and amyotrophic lateral sclerosis," Journal of the Neurological Sciences, vol. 63, no. 2, pp. 241-250, 1984.

[122] T. Ishii, S. Haga, and S. Tokutake, "Presence of neurofilament protein in Alzheimer's neurofibrillary tangles (ANT). An immunofluorescent study," Acta Neuropathologica, vol. 48, no.

2, pp. 105-112, 1979.

[123] N. Nukina, K. S. Kosik, and D. J. Selkoe, "Recognition of Alzheimer paired helical filaments by monoclonal neurofilament antibodies is due to crossreaction with tau protein," Proceedings of the National Academy of Sciences of the United States of America, vol. 84, no. 10, pp. 3415-3419, 1987.

[124] J. E. Goldman, S. H. Yen, F. C. Chui, and N. S. Peress, "Lewy bodies of Parkinson's disease contain neurofilament antigens," Science, vol. 221, no. 4615, pp. 1082-1084, 1983.

[125] P. G. Galloway, P. Mulvihill, and G. Perry, "Filaments of Lewy bodies contain insoluble cytoskeletal elements," The American Journal of Pathology, vol. 140, no. 4, pp. 809-822, 1992.

[126] P. Vogel, M. Gabriel, H. H. Goebel, and P. J. Dyck, "Hereditary motor sensory neuropathy type II with neurofilament accumulation: new finding or new disorder?" Annals of Neurology, vol. 17, no. 5, pp. 455-461, 1985.

[127] J. Peiffer, W. Schlote, A. Bischoff, E. Boltshauser, and G. Muller, "Generalized giant axonal neuropathy. A filament-forming disease of neuronal, endothelial, glial, and Schwann cells in a patient without kinky hair," Acta Neuropathologica, vol. 40, no. 3, pp. 213-218, 1977

[128] N. J. Cairns, V. Zhukareva, K. Uryu et al., "a-internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease," The American Journal of Pathology, vol. 164, no. 6, pp. 2153-2161, 2004.

[129] H. Uchikado, G. Shaw, D.-S. Wang, and D. W. Dickson, "Screening for neurofilament inclusion disease using a-internexin immunohistochemistry," Neurology, vol. 64, no. 9, pp. 16581659, 2005.

[130] R. Medori, L. Autilio-Gambetti, S. Monaco, and P. Gambetti, "Experimental diabetic neuropathy: impairment of slow transport with changes in axon cross-sectional area," Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 22, pp. 7716-7720, 1985.

[131] R. Medori, H. Jenich, L. Autilio-Gambetti, and P. Gambetti, "Experimental diabetic neuropathy: similar changes of slow axonal transport and axonal size in different animal models," Journal of Neuroscience, vol. 8, no. 5, pp. 1814-1821, 1988.

[132] R. Perrot, R. Berges, A. Bocquet, and J. Eyer, "Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration," Molecular Neurobiology, vol. 38, no. 1, pp. 27-65, 2008.

[133] J. W. Griffin, I. Parhad, B. Gold, D. L. Price, P. N. Hoffman, and K. Fahnestock, "Axonal transport of neurofilament proteins in IDPN neurotoxicity," NeuroToxicology, vol. 6, no. 4, pp. 43-54, 1985.

[134] J. W Griffin, P. N . Hoffman, A . W Clark, P. T. Carroll, and D. L. Price, "Slow axonal transport of neurofilament proteins: impairment by [beta],[beta]' iminodipropionitrile administration," Science, vol. 202, no. 4368, pp. 633-635, 1978.

[135] J. Eyer, W. G. Mclean, and J.-F. Leterrier, "Effect of a single dose of [beta],[beta]'-iminodipropionitrile in vivo on the properties of neurofilaments in vitro: comparison with the effect of iminodipropionitrile added directly to neurofilaments in vitro," Journal of Neurochemistry, vol. 52, no. 6, pp. 1759-1765, 1989.

[136] T. Kadota and K. Kadota, "Neurofilament hypertrophy induced in the rabbit spinal cord after intracisternal injection of aluminum chloride," Journal of Toxicological Sciences, vol. 3, no. 1, pp. 57-67, 1978.

[137] L. F. Eng and R. S. Ghirnikar, "GFAP and astrogliosis," Brain Pathology, vol. 4, no. 3, pp. 229-237, 1994.

[138] L. Mucke and M. Eddleston, "Astrocytes in infectious and immune-mediated diseases of the central nervous system," The FASEB Journal, vol. 7, no. 13, pp. 1226-1232, 1993.

[139] M. Pekny and M. Pekna, "Astrocyte intermediate filaments in CNS pathologies and regeneration," Journal of Pathology, vol. 204, no. 4, pp. 428-437, 2004.

[140] R. Li, A. B. Johnson, G. Salomons et al., "Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease," Annals of Neurology, vol. 57, no. 3, pp. 310326, 2005.

[141] R. A. Quinlan, M. Brenner, J. E. Goldman, and A. Messing, "GFAP and its role in Alexander disease," Experimental Cell Research, vol. 313, no. 10, pp. 2077-2087, 2007

[142] M. B. Omary, N.-O. Ku, G.-Z. Tao, D. M. Toivola, and J. Liao, "'Heads and tails'of intermediate filament phosphorylation: multiple sites and functional insights," Trends in Biochemical Sciences, vol. 31, no. 7, pp. 383-394, 2006.

[143] R. A. Nixon and R. K. Sihag, "Neurofilament phosphorylation: a new look at regulation and function," Trends in Neurosciences, vol. 14, no. 11, pp. 501-506, 1991.

[144] M. Inagaki, Y. Matsuoka, K. Tsujimura et al., "Dynamic property of intermediate filaments: regulation by phosphorylation," BioEssays, vol. 18, no. 6, pp. 481-487, 1996.

[145] P. Grant and H. C. Pant, "Neurofilament protein synthesis and phosphorylation," Journal of Neurocytology, vol. 29, no. 11-12, pp. 843-872, 2000.

[146] B. T Helfand, L. Chang, and R. D. Goldman, "Intermediate filaments are dynamic and motile elements of cellular architecture," Journal of Cell Science, vol. 117, no. 2, pp. 133-141, 2004.

[147] R. K. Sihag, M. Inagaki, T Yamaguchi, T B. Shea, and H. C. Pant, "Role of phosphorylation on the structural dynamics and function of types III and IV intermediate filaments," Experimental Cell Research, vol. 313, no. 10, pp. 2098-2109, 2007

[148] P. Pierozan, A. Zamoner, A. Krombauer Soska et al., "Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats," Experimental Neurology, vol. 224, no. 1, pp. 188-196, 2010.

[149] P. Pierozan, A. Zamoner, A. K. Soska et al., "Signaling mechanisms downstream of quinolinic acid targeting the cytoskeleton of rat striatal neurons and astrocytes," Experimental Neurology, vol. 233, no. 1, pp. 391-399, 2012.

[150] L. Zanatta, P. B. Goulart, R. Goncalves et al., "1[alpha],25- Dihydroxyvitamin D3 mechanism of action: modulation of L-type calcium channels leading to calcium uptake and intermediate filament phosphorylation in cerebral cortex of young rats," Biochimica etBiophysicaActa: Molecular Cell Research, vol. 1823, no. 10, pp. 1708-1719, 2012.

[151] A. Zamoner, C. Funchal, L. Heimfarth, F. R. M. B. Silva, and R. Pessoa-Pureur, "Short-term effects of thyroid hormones on cytoskeletal proteins are mediated by GABAergic mechanisms in slices of cerebral cortex from young rats," Cellular and Molecular Neurobiology, vol. 26, no. 2, pp. 209-224, 2006.

[152] A. Zamoner, P. Pierozan, L. F. Vidal et al., "Vimentin phosphorylation as a target of cell signaling mechanisms induced by 1[alpha],25-dihydroxy vitamin D3 in immature rat testes," Steroids, vol. 73, no. 14, pp. 1400-1408, 2008.

[153] K. Nishizawa, T Yano, M. Shibata et al., "Specific localization of phosphointermediate filament protein in the constricted area of dividing cells," Journal of Biological Chemistry, vol. 266, no. 5, pp. 3074-3079, 1991.

[154] Y. Matsuoka, K. Nishizawa, T Yano et al., "Two different protein kinases act on a different time schedule as glial filament kinases during mitosis," The EMBO Journal, vol. 11, no. 8, pp. 2895-2902, 1992.

[155] M. Inagaki, Y. Gonda, K. Nishizawa et al., "Phosphorylation sites linked to glial filament disassembly in vitro locate in a nona-helical head domain," Journal of Biological Chemistry, vol. 265, no. 8, pp. 4722-4729, 1990.

[156] M. Inagaki, Y. Nakamura, M. Takeda, T. Nishimura, and N. Inagaki, "Glial fibrillary acidic protein: dynamic property and regulation by phosphorylation," Brain Pathology, vol. 4, no. 3, pp. 239-243, 1994.

[157] R. K. Sihag and R. A. Nixon, "Identification of Ser-55 as a major protein kinase a phosphorylation site on the 70-kDa subunit of neurofilaments: early turnover during axonal transport," Journal of Biological Chemistry, vol. 266, no. 28, pp. 18861-18867, 1991.

[158] R. K. Sihag, H. Jaffe, R. A. Nixon, and X. Rong, "Serine-23 is a major protein kinase A phosphorylation site on the aminoterminal head domain of the middle molecular mass subunit of neurofilament proteins," Journal of Neurochemistry, vol. 72, no. 2, pp. 491-499, 1999.

[159] R. Hashimoto, Y. Nakamura, S. Komai et al., "Site-specific phosphorylation of neurofilament-L is mediated by calcium/ calmodulin-dependent protein kinase II in the apical dendrites during long-term potentiation," Journal of Neurochemistry, vol. 75, no. 1, pp. 373-382, 2000.

[160] Y. Gonda, K. Nishizawa, S. Ando et al., "Involvement of protein kinase C in the regulation of assembly-disassembly of neurofilaments in vitro," Biochemical and Biophysical Research Communications, vol. 167, no. 3, pp. 1316-1325, 1990.

[161] C. C. Floyd, P. Grant, P. E. Gallant, and H. C. Pant, "Principal neurofilament-associated protein kinase in squid axoplasm is related to casein kinase I," Journal of Biological Chemistry, vol. 266, no. 8, pp. 4987-4994, 1991.

[162] B. A. Hollander, G. S. Bennett, and G. Shaw, "Localization of sites in the tail domain of the middle molecular mass neurofilament subunit phosphorylated by a neurofilament-associated kinase and by casein kinase I," Journal of Neurochemistry, vol. 66, no. 1, pp. 412-420, 1996.

[163] B. I. Giasson and W. E. Mushynski, "Study of proline-directed protein kinases involved in phosphorylation of the heavy neurofilament subunit," Journal of Neuroscience, vol. 17, no. 24, pp. 9466-9472, 1997.

[164] S. Guidato, N. P. S. Bajaj, and C. C. J. Miller, "Cellular phosphorylation of neurofilament heavy-chain by cyclin-dependent kinase-5 masks the epitope for monoclonal antibody N52," Neuroscience Letters, vol. 217, no. 2-3, pp. 157-160, 1996.

[165] J. Brownlees, A. Yates, N. P. Bajaj et al., "Phosphorylation of neurofilament heavy chain side-arms by stress activated protein kinase-1b/Jun N-terminal kinase-3," Journal of Cell Science, vol. 113, no. 3, pp. 401-407, 2000.

[166] B. I. Giassont and W. E. Mushynski, "Aberrant stress-induced phosphorylation of perikaryal neurofilaments," Journal of Biological Chemistry, vol. 271, no. 48, pp. 30404-30409, 1996.

[167] N. D. Amin, N. G. Ahn, H. Jaffe, C. A. Winters, P. Grant, and H. C. Pant, "Mitogen-activated protein kinases (Erk1,2) phosphorylate lys-ser-pro (KSP) repeats in neurofilament proteins NF-H and NF-M," Journal of Neuroscience, vol. 18, no. 11, pp. 4008-4021, 1998.

[168] K. Taranath Shetty, M. Takahashi, P. Grant, and H. C. Pant, "Cdk5 and MAPK are associated with complexes of cytoskeletal proteins in rat brain," Molecular Brain Research, vol. 76, pp. 229-236, 2000.

[169] S. Guidato, L.-H. Tsai, J. Woodgett, and C. C. J. Miller, "Differential cellular phosphorylation of neurofilament heavy side-arms by glycogen synthase kinase-3 and cydin-dependent kinase-5," Journal of Neurochemistry, vol. 66, no. 4, pp. 1698-1706, 1996.

[170] S. Roy, P. Coffee, G. Smith, R. K. H. Liem, S. T. Brady, and M. M. Black, "Neurofilaments are transported rapidly but intermittently in axons: implications for slow axonal transport," Journal of Neuroscience, vol. 20, no. 18, pp. 6849-6861, 2000.

[171] L. Wang, C.-L. Ho, D. Sun, R. K. H. Liem, and A. Brown, "Rapid movement of axonal neurofilaments interrupted by prolonged pauses," Nature Cell Biology, vol. 2, no. 3, pp. 137-141, 2000.

[172] C.-H. Xia, E. A. Roberts, L.-S. Her et al., "Abnormal neurofilament transport caused by targeted disruption of neuronal kinesin heavychain KIF5A," Journal of Cell Biology, vol. 161, no. I, pp. 55-66, 2003.

[173] O. I. Wagner, J. Ascaho, M. Tokito, J.-F. Leterrier, P A. Janmey, and E. L. F. Holzbaur, "The interaction of neurofilaments with the microtubule motor cytoplasmic dynein," Molecular Biology of the Cell, vol. 15, no. 11, pp. 5092-5100, 2004.

[174] A. Uchida, N. H. Alami, and A. Brown, "Tight functional coupling of kinesin-1A and dynein motors in the bidirectional transport of neurofilaments," Molecular Biology of the Cell, vol. 20, no. 23, pp. 4997-5006, 2009.

[175] S. O. Loureiro, L. Romao, T. Alves et al., "Homocysteine induces cytoskeletal remodeling and production of reactive oxygen species in cultured cortical astrocytes," Brain Research, vol. 1355, pp. 151-164, 2010.

[176] A. Zamoner, L. Heimfarth, S. Oliveira Loureiro, C. Royer, F. R. Mena Barreto Silva, and R. Pessoa-Pureur, "Nongenomic actions of thyroxine modulate intermediate filament phosphorylation in cerebral cortex of rats," Neuroscience, vol. 156, no. 3, pp. 640-652, 2008.

[177] R. Pessoa-Pureur and M. Wajner, "Cytoskeleton as a potential target in the neuropathology of maple syrup urine disease: insight from animal studies," Journal of Inherited Metabolic Disease, vol. 30, no. 5, pp. 664-672, 2007.

[178] S. O. Loureiro, L. Heimfarth, P D. L. Pelaez et al., "Homocysteine activates calcium-mediated cell signaling mechanisms targeting the cytoskeleton in rat hippocampus," International Journal of Developmental Neuroscience, vol. 26, no. 5, pp. 447-455, 2008.

[179] L. Heimfarth, S. O. Loureiro, M. F. Dutra et al., "In vivo treatment with diphenyl ditelluride induces neurodegeneration in striatum of young rats: implications of MAPK and Akt pathways," Toxicology and Applied Pharmacology, vol. 264, no. 2, pp. 143-152, 2012.

[180] L. Heimfarth, S. O. Loureiro, A. Zamoner et al., "Effects of in vivo treatment with diphenyl ditelluride on the phosphorylation of cytoskeletal proteins in cerebral cortex and hippocampus of rats," NeuroToxicology, vol. 29, no. 1, pp. 40-47, 2008.

[181] L. Heimfarth, S. O. Loureiro, K. P Reis et al., "Cross-talk among intracellular signaling pathways mediates the diphenyl ditelluride actions on the hippocampal cytoskeleton of young rats," Chemical Research in Toxicology, vol. 24, no. 10, pp. 1754-1764, 2011.

[182] L. Heimfarth, S. O. Loureiro, K. P Reis et al., "Diphenyl ditelluride induces hypophosphorylation of intermediate filaments through modulation of DARPP-32-dependent pathways in cerebral cortex of young rats," Archives of Toxicology, vol. 86, no. 2, pp. 217-230, 2012.

[183] L. Heimfarth, K. P. Reis, S. O. Loureiro, B. O. de Lima, J. B. T. da Rocha, and R. Pessoa-Pureur, "Exposure of young rats to diphenyl ditelluride during lactation affects the homeostasis of the cytoskeleton in neural cells from striatum and cerebellum," NeuroToxicology, vol. 33, no. 5, pp. 1106-1116, 2012.

[184] J. W. Putney Jr. and G. S. J. Bird, "The inositol phosphatecalcium signaling system in nonexcitable cells," Endocrine Reviews, vol. 14, no. 5, pp. 610-631, 1993.

[185] M. J. Berridge, "Capacitative calcium entry," Biochemical Journal, vol. 312, no. 1, pp. 1-11, 1995.

[186] D. E. Clapham, "Calcium signaling," Cell, vol. 80, no. 2, pp. 259-268, 1995.

[187] D. E. Warren, P E. Bidder, J. P Clark et al., "Hypothermia and rewarming injury in hippocampal neurons involve intracellular [Ca.sup.2+] and glutamate excitotoxicity," Neuroscience, vol. 207, pp. 316-325, 2012.

[188] C. Mathiesen, K. Caesar, K. Thomsen et al., "Activity-dependent increases in local oxygen consumption correlate with postsynaptic currents in the mouse cerebellum in vivo," Journal of Neuroscience, vol. 31, no. 50, pp. 18327-18337, 2011.

[189] T. Kawanai, "Triclosan, an environmental pollutant from health care products, evokes charybdotoxin-sensitive hyperpolarization in rat thymocytes," Environmental Toxicology and Pharmacology, vol. 32, no. 3, pp. 417-422, 2011.

[190] G. RamaRao and B. K. Bhattacharya, "Multiple signal transduction pathways alterations during nerve agent toxicity," Toxicology Letters, vol. 208, no. 1, pp. 16-22, 2012.

[191] Y.-F. Chen, Y.-T. Chen, W.-T. Chiu, and M.-R. Shen, "Remodeling of calcium signaling in tumor progression," Journal of Biomedical Science, vol. 20, no. 1, article 23, 2013.

[192] T. Call, D. Ottolini, and M. Brini, "Calcium and endoplasmic reticulum-mitochondria tethering in neuro degeneration," DNA and Cell Biology, vol. 32, no. 4, pp. 140-146, 2013.

[193] K. Hakansson, M. Lindskog, L. Pozzi, A. Usiello, and G. Fisone, "DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia," Parkinsonism and Related Disorders, vol. 10, no. 5, pp. 281-286, 2004.

[194] B.-S. Li, L. Zhang, J. Gu, N. D. Amin, and H. C. Pant, "Integrin [alpha]1[beta]1-mediated activation of cyclin-dependent kinase 5 activity is involved in neurite outgrowth and human neurofilament protein H Lys-Ser-Pro tail domain phosphorylation," Journal of Neuroscience, vol. 20, no. 16, pp. 6055-6062, 2000.

[195] D. Willoughby and D. M. F. Cooper, "[Ca.sup.2+] stimulation of adenylyl cyclase generates dynamic oscillations in cyclic AMP," Journal of Cell Science, vol. 119, no. 5, pp. 828-836, 2006.

[196] S. Strack, M. A. Barban, B. E. Wadzinski, and R. J. Colbran, "Differential inactivation of postsynaptic density-associated and soluble [Ca.sup.2+]/calmodulin-dependent protein kinase II by protein phosphatases 1 and 2A," Journal of Neurochemistry, vol. 68, no. 5, pp. 2119-2128, 1997.

[197] S. Strack, R. S. Westphal, R. J. Colbran, F. F. Ebner, and B. E. Wadzinski, "Protein serine/threonine phosphatase 1 and 2A associate with and dephosphorylate neurofilaments," Molecular Brain Research, vol. 49, no. 1-2, pp. 15-28, 1997.

[198] Y. Yoshimura, Y. Sogawa, and T Yamauchi, "Protein phosphatase 1 is involved in the dissociation of [Ca.sup.2+]/calmodulin-dependent protein kinase II from postsynaptic densities," FEBS Letters, vol. 446, no. 2-3, pp. 239-242, 1999.

[199] R. Liu, X.-W. Zhou, H. Tanila et al., "Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology: in focus," Journal of Cellular and Molecular Medicine, vol. 12, no. 1, pp. 241-257, 2008.

[200] T Saito, H. Shima, Y. Osawa et al., "Neurofilament-associated protein phosphatase 2A: its possible role in preserving neurofilaments in filamentous states," Biochemistry, vol. 34, no. 22, pp. 7376-7384, 1995.

[201] J.-J. Pei, I. Grundke-Iqbal, K. Iqbal, N. Bogdanovic, B. Winblad, and R. F. Cowburn, "Elevated protein levels of protein phosphatases PP-2A and PP-2B in astrocytes of Alzheimer's disease temporal cortex," Journal of Neural Transmission, vol. 104, no. 11-12, pp. 1329-1338, 1997.

[202] X. Yin, T O. Crawford, J. W. Griffin et al., "Myelin-associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons," Journal of Neuroscience, vol. 18, no. 6, pp. 1953-1962, 1998.

[203] B. Picconi, D. Centonze, K. Hakansson et al., "Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia," Nature Neuroscience, vol. 6, no. 5, pp. 501-506, 2003.

[204] C. Funchal, P. de Lima Pelaez, S. Oliveira Loureiro et al., "aketoisocaproic acid regulates phosphorylation of intermediate filaments in postnatal rat cortical slices through ionotropic glutamatergic receptors," Developmental Brain Research, vol. 139, no. 2, pp. 267-276, 2002.

[205] F. E. Jensen, "The role of glutamate receptor maturation in perinatal seizures and brain injury," International Journal of Developmental Neuroscience, vol. 20, no. 3-5, pp. 339-347, 2002.

[206] C. Wang and F. E. Jensen, "Age dependence of NMDA receptor involvement in epileptiform activity in rat hippocampal slices," Epilepsy Research, vol. 23, no. 2, pp. 105-113, 1996.

[207] J. W. McDonald, F. S. Silverstein, and M. V. Johnston, "Neurotoxicity of N-methyl-D-aspartate is markedly enhanced in developing rat central nervous system," Brain Research, vol. 459, no. 1, pp. 200-203, 1988.

[208] S. Ozawa, H. Kamiya, and K. Tsuzuki, "Glutamate receptors in the mammalian central nervous system," Progress in Neurobiology, vol. 54, no. 5, pp. 581-618, 1998.

[209] D. E. Pellegrini-Giampietro, M. V. L. Bennett, and R. S. Zukin, "Differential expression of three glutamate receptor genes in developing rat brain: an in situ hybridization study," Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 10, pp. 4157-4161, 1991.

[210] R. Perrot and J. Eyer, "Neuronal intermediate filaments and neurodegenerative disorders," Brain Research Bulletin, vol. 80, no. 4-5, pp. 282-295, 2009.

[211] S. C. Bondy and A. Campbell, "Developmental neurotoxicology," Journal of Neuroscience Research, vol. 81, no. 5, pp. 605-612, 2005.

[212] S. R. Haut, J. Veliskova, and L. Moshe, "Susceptibility of immature and adult brains to seizure effects," The Lancet Neurology, vol. 3, pp. 608-617, 2004.

[213] M. J. Carden, J. Q. Trojanowski, W. W. Schlaepfer, and V. M.Y. Lee, "Two-stage expression of neurofilament polypeptides during rat neurogenesis with early establishment of adult phosphorylation patterns," Journal of Neuroscience, vol. 7, no. 11, pp. 3489-3504, 1987.

[214] I. Sanchez, L. Hassinger, R. K. Sihag, D. W. Cleveland, P. Mohan, and R. A. Nixon, "Local control of neurofilament accumulation during radial growth of myelinating axons in vivo: selective role of site-specific phosphorylation," Journal of Cell Biology, vol. 151, no. 5, pp. 1013-1024, 2000.

[215] Z. Xie, B. A. Samuels, and L.-H. Tsai, "Cyclin-dependent kinase 5 permits efficient cytoskeletal remodeling: a hypothesis on neuronal migration," Cerebral Cortex, vol. 16, supplement 1, pp. i64-i68, 2006.

[216] K. F. Tolias, J. G. Duman, and K. Um, "Control of synapse development and plasticity by Rho GTPase regulatory proteins," Progress in Neurobiology, vol. 94, no. 2, pp. 133-148, 2011.

[217] M. Fujimura, F. Usuki, M. Sawada, and A. Takashima, "Methylmercury induces neuropathological changes with tau hyperphosphorylation mainly through the activation of the c-jun-N-terminal kinase pathway in the cerebral cortex, but not in the hippocampus of the mouse brain," NeuroToxicology, vol. 30, no. 6, pp. 1000-1007, 2009.

[218] M. V. Sofroniew and H. V. Vinters, "Astrocytes: biology and pathology," Acta Neuropathologica, vol. 119, no. 1, pp. 7-35, 2010.

[219] C. Farina, F. Aloisi, and E. Meinl, "Astrocytes are active players in cerebral innate immunity," Trends in Immunology, vol. 28, no. 3, pp. 138-145, 2007

[220] C. M. Liberto, P. J. Albrecht, L. M. Herx, V. W. Yong, and S. W. Levison, "Pro-regenerative properties of cytokine-activated astrocytes," Journal of Neurochemistry, vol. 89, no. 5, pp. 10921100, 2004.

[221] H. Hayashi, R. B. Campenot, D. E. Vance, and J. E. Vance, "Protection of neurons from apoptosis by apolipoprotein e-containing lipoproteins does not require lipoprotein uptake and involves activation of phospholipase Cy1 and inhibition of calcineurin," Journal of Biological Chemistry, vol. 284, no. 43, pp. 29605-29613, 2009.

[222] M. R. Vargas and J. A. Johnson, "The Nrf2-ARE cytoprotective pathway in astrocytes," Expert Reviews in Molecular Medicine, vol. 11, article e17, 2009.

[223] L. M. V de Almeida, C. Funchal, C. Gottfried, M. Wajner, and R. Pessoa-Pureur, "Propionic acid induces cytoskeletal alterations in cultured astrocytes from rat cerebral cortex," Metabolic Brain Disease, vol. 21, no. 1, pp. 51-62, 2006.

[224] S. M. Sullivan, R. K. P. Sullivan, S. M. Miller et al., "Phosphorylation of GFAP is associated with injury in the neonatal pig hypoxic-ischemic brain," Neurochemical Research, vol. 37, no. 11, pp. 2364-2378, 2012.

[225] H. C. Pant, "Dephosphorylation of neurofilament proteins enhances their susceptibility to degradation by calpain," Biochemical Journal, vol. 256, no. 2, pp. 665-668, 1988.

[226] J. Zhou, H. Wang, Y. Feng, and J. Chen, "Increased expression of cdk5/p25 in N2a cells leads to hyperphosphorylation and impaired axonal transport of neurofilament proteins," Life Sciences, vol. 86, no. 13-14, pp. 532-537, 2010.

[227] J.-F. Collard, F. Cote, and J.-P. Julien, "Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis," Nature, vol. 375, no. 6526, pp. 61-64, 1995.

[228] I. Toyoshima, K. Kato, M. Sugawara, C. Wada, and O. Masamune, "Kinesin accumulation in chick spinal axonal swellings with [beta],[beta]',-iminodipropionitrile (IDPN) intoxication," Neuroscience Letters, vol. 249, no. 2-3, pp. 103-106, 1998.

[229] M. M. Black and V M.-Y. Lee, "Phosphorylation of neurofilament proteins in intact neurons: demonstration of phosphorylation in cell bodies and axons," Journal of Neuroscience, vol. 8, no. 9, pp. 3296-3305, 1988.

[230] K. Jaskova, M. Pavlovicova, and D. Jurkovicova, "Calcium transporters and their role in the development of neuronal disease and neuronal damage," General Physiology and Biophysics, vol. 31, no. 4, pp. 375-382, 2012.

[231] P. Lampert, F. Garro, and A. Pentschew, "Tellurium neuropathy," Acta Neuropathologica, vol. 15, no. 4, pp. 308-317, 1970.

[232] A. A. Nar, B. Diesel, F. Desor et al., "Neurodevelopmental and behavioral toxicity of lactational exposure to the sum of six indicatorn on-dioxin-like-polychlorinated biphenyls (P6NDLPCBs) in offspring mice," Toxicology, vol. 299, pp. 44-54, 2012.

[233] A. A. Elnar, B. Diesel, F. Desor et al., "Neurodevelopmental and behavioral toxicity via lactational exposure to the sum of six indicator non-dioxin-like-polychlorinated biphenyls (6 [pounds sterling] NDLPCBs) in mice," Toxicology, vol. 299, no. 1, pp. 44-54, 2012.

[234] R. W. Tyl and W. F. Sette, "Workshop on the qualitative and quantitative comparability of human and animal developmental neurotoxicity, work group III report: weight of evidence and quantitative evaluation of developmental neurotoxicity data," Neurotoxicology and Teratology, vol. 12, no. 3, pp. 275-280, 1990.

[235] M. Dubovicky, "Neurobehavioral manifestations of developmental impairment of the brain," Interdisciplinary Toxicology, vol. 3, no. 2, pp. 59-67, 2010.

[236] G. M. Abu-Taweel, J. S. Ajarem, and M. Ahmad, "Neurobehavioral toxic effects of perinatal oral exposure to aluminum on the developmental motor reflexes, learning, memory and brain neurotransmitters of mice offspring," Pharmacology Biochemistry and Behavior, vol. 101, no. 1, pp. 49-56, 2012.

[237] S. A. Hulea, R. Olinescu, S. Nita, D. Crocnan, and F. A. Kummerow, "Cigarette smoking causes biochemical changes in blood that are suggestive of oxidative stress: a case-control study," Journal of Environmental Pathology, Toxicology and Oncology, vol. 14, no. 3-4, pp. 173-180, 1995.

Regina Pessoa-Pureur, (1) Luana Heimfarth, (1) and Joao B. Rocha (2)

(1) Departamento de Bioquimica, Instituto de Ciencias Basicas da Saude, UFRGS, 90035-003 Porto Alegre, RS, Brazil

(2) Departamento de Bioquimica e Biologia Molecular, Centro de Ciencias Naturais e Exatas, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil

Correspondence should be addressed to Joao B. Rocha;

Received 4 February 2014; Accepted 26 February 2014; Published 22 June 2014

Academic Editor: Maria Elena Chanez-Cardenas
COPYRIGHT 2014 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Pessoa-Pureur, Regina; Heimfarth, Luana; Rocha, Joao B.
Publication:Oxidative Medicine and Cellular Longevity
Article Type:Report
Geographic Code:3BRAZ
Date:Jan 1, 2014
Previous Article:Exercise training preserves ischemic preconditioning in aged rat hearts by restoring the myocardial polyamine pool.
Next Article:Evaluation of neonatal streptozotocin induced diabetic rat model for the development of cataract.

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters